Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS
Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS

A COMPREHENSIVE OVERVIEW OF OUR RESEARCH

Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoconomics in place for ready use across their customers and therapeutic areas.

For three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through June 2014.

For more information on our research activities and health care consulting practice, please visit our website, www.analysisgroup.com.
CONTENTS

ANEMIA 1
ASTHMA 3
CARDIOVASCULAR DISEASE 4
DERMATOLOGY 9
DIABETES 14
ENDOCRINOLOGY 19
GASTROINTESTINAL DISORDERS 19
HEMATOLOGY 23
MENTAL HEALTH 24
MUSCULOSKELETAL DISEASE 33
NEPHROLOGY 34
NEUROLOGICAL DISORDERS 36
OBESITY, METABOLIC, AND NUTRITIONAL DISORDERS 38
ONCOLOGY 38
OTHER CONDITIONS AND TOPICS 49
OVERACTIVE BLADDER 58
PAIN AND PRESCRIPTION OPIOIDS 58
RESPIRATORY DISEASE 60
RHEUMATOLOGY 64
WOMEN'S HEALTH 66
ANEMIA

Age-related emergency department reliance (EDR) and healthcare resource utilization in patients with sickle cell disease (SCD)
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS

Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Jordan L, Duh M, Vekeman F, Matter S, Bieri C, Sasane M

Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs
Authors: Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease
Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS

Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings
Authors: Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P

Dosing pattern and cost comparison of epoetin alfa and darbepeotin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P

Comment: The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepeotin alfa
Authors: Lefebvre P, Vekeman F, Crémieux PY

Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: Data from multicenter clinical practices
Authors: Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J

Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin
Authors: Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: Observations from a large managed-care database
Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Tak Piech C, Lefebvre P

An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach
Authors: Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V

Anemia and the risk of injurious falls in a community-dwelling elderly population
Authors: Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT

Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: A meta-analysis
Authors: Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S
Management of anaemia: A critical and systematic review of the cost-effectiveness of erythropoiesis-stimulating agents


**Authors:** Duh MS, Weiner J R, White LA, Lefebvre P, Greenberg PE

Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen


**Authors:** Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A

Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?


**Authors:** Wu WK, Duh MS, Lefebvre P

Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease


**Authors:** Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH

Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer


**Authors:** Gosselin A, McKenzie RS, Lefebvre P, Mody SH, Piech CT, Duh MS

Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: An analysis of four observational studies


**Authors:** Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS

Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa


**Authors:** Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Crémiieux PY

Impact and treatment of anemia in the elderly: Clinical, epidemiological and economic perspectives


**Authors:** Duh MS, Latypova A, Greenberg PE

Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: A Canadian application

**Publication.** J Oncol Pharm Practice. 2006 Sep; 12(3):165-78.

**Authors:** Crémiieux PY, Vekeman F, Lefebvre P

Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy


**Authors:** Chu E, Einhorn LH, Lefebvre P

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia


**Authors:** Campos SM, Duh MS, Lefebvre P, Rosberg J

The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia


**Authors:** Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Piech CT

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve


**Authors:** Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ

Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia


**Authors:** Duh MS, Mark TL
Dose conversion and cost-effectiveness of erythropoietic therapies in chemotherapy-related anaemia: A meta-analysis
Authors: Rosberg J H, Ben-Hamadi R, Crémieux PY, Fastenau J M, Piech CT

Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH

Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia
Authors: Crémieux PY, Fastenau J M, Kosicki G, Piech CT, Fendrick AM

The CRIT study: Anemia and blood transfusion in the critically ill—current clinical practice in the United States
Authors: Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ

Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
Authors: Crawford J, Cella D, Cleeland CS, Crémieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA

Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy
Authors: Gabrilove JL, Sarokhan B, Crémieux PY

Anemia-related costs for cancer patients
Authors: Barnett A, Crémieux PY, Fendrick AM, George M, Slavin MB

Costs associated with anemia and cancer
Authors: Crémieux PY, Gubens M, Holland M, Slavin MB

Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anemia
Authors: Crémieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB

ASTHMA

Burden of illness of patients with allergic asthma versus non-allergic asthma
Publication: J Asthma. 2013 Jul 9. [Epub ahead of print]
Authors: Lafeuille MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P

Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma
Authors: Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P

Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma
Authors: Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K

Concomitant asthma medication use in patients receiving omalizumab: Results from three large insurance claims databases
Authors: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P

Asthma severity categorization using a claims-based algorithm or pulmonary function testing
Authors: Birnbaum HG, Ivanova JI, Yu AP, Hsieh M, Seal B, Emani S, Rosiello R, Colice GL

Adherence to inhaled corticosteroid use and local adverse events in persistent asthma
Authors: Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL
CARDIOVASCULAR DISEASE

Hospital length of stay: Does rivaroxaban reduce impatient stay compared to warfarin among patients with non-valvular atrial fibrillation
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Laliberté F, Pilon D, Raut M, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P

Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damron CV, Schein JR, Lefebvre P

The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Penn MS, Yenikomshian MA, Cummings AK, Damron JM, Purvis S, Birnbaum HG

Cost of venous thromboembolism (VTE) among hospitalized patients in China
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y

Effect of prasugrel vs clopidogrel on hospital readmission among acute coronary syndrome patients treated with prasugrel
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)

Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants
Authors: Laliberte F, Coleman C, Bookhart B, Lefebvre P, Cloutier M, Damraju CV, Schein JR, Kaatz S

Specialized adult congenital heart disease care: the impact of policy on mortality
Authors: Mylottte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A

Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China
Authors: Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y

Long-term cost-effectiveness of transcatheter versus surgical closure of secundum atrial septal defect in adults
Authors: Mylotte D, Quenneville SP, Kotowycz MA, Xie X, Brophy JM, Ionescu-Ittu R, Martucci G, Pilote L, Therrien J, Marelli AJ

Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism
Publication: J Med Econ. 2014 Jan;17(1):52-64
Authors: Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?
Authors: Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P

All-cause and disease-related health care costs associated with recurrent venous thromboembolism
Authors: Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S

Impact of the FDA safety communication on prescription trends of clopidogrel in combination with proton pump inhibitors
Abstract: American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting and Postgraduate Course, October 11-16, 2013, San Diego, CA (Poster)
Authors: Guérin A, Mody R, Carter V, Wu EQ

Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors
Authors: Rushani D, Kaufman JS, Ionescu-Ittu R, Mackie AS, Pilote L, Therrien J, Marelli AJ
Treating acute heart failure in the elderly: A U.S. comparison of three inpatient treatment alternatives

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Podium presentation)

Authors: Gradman A, Vekeman F, Eldar-Lissai A, Trahey A, Lecomte P, Ong SH, Duh, MS

Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension


Authors: Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism


Authors: Laliberté F, Bookhart BK, Nelson WW, Lefebvre P, Schein J R, Rondeau-Leclaire J, Duh MS

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: A matched cohort study


Authors: Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.

Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals’ perspectives


Authors: Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ

Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review

Abstract: 2012 Canadian Hypertension Congress, Toronto, Canada, 25-28 October, 2012 (Poster)

Authors: Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S

Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide

Abstract: AMCP Educational Conference 2012, Cincinnati, OH, 3-5 October, 2012 (Poster)

Authors: Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J

Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide

Abstract: AMCP Educational Conference 2012, Cincinnati, Ohio, 3-5 October, 2012 (Poster)

Authors: Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS Wu EQ

Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients


Authors: Laliberté F, Nelson WW, Lefebvre P, Schein J R, Rondeau-Leclaire J, Duh MS

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries


Authors: Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S

Compliance and persistence with nebivolol vs. diuretics as first add-on hypertension treatment

Abstract: ASH 27th Annual Scientific Meeting & Exposition, New York, NY, 19-22 May, 2012 (Poster)

Authors: Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu EQ

Associations of hypertension with risk of cardiovascular events among Chinese stroke patients in the U.S.

Abstract: ASH 27th Annual Scientific Meeting and Exposition, New York, NY, 19-22 May, 2012 (Poster)

Authors: Fung G, Kahler K, Xie J, Marynchenko M, Wu EQ, Kam I, Yang W
Risk of cardiovascular events associated with hypertension among Chinese and Caucasian stroke patients in the U.S.
Publication: ASH 27th Annual Scientific Meeting and Exposition, New York, NY, 19-22 May, 2012 (Poster)
Authors: Fung G, Kahler K, Xie J, Liu NS, Wu EQ, Kam I, Yang W

Persistence with nebivolol in the treatment of hypertension: A retrospective claims analysis
Authors: Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S

Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy
Authors: Guérin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS

Resource utilization and costs following hospitalization of patients with chronic heart failure in the U.S.
Authors: Korves C, Eldar-Lissai A, McHale J, Lafuille MH, Hwa Ong S, Duh MS

Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia
Authors: Signorovitch JE, Brainsky A, Grotzinger KM

Excess costs associated with patients with pulmonary arterial hypertension in a U.S. privately insured population
Publication: Appl Health Econ Health Policy. 2011 Sep 1; 9(5):293-303.
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T

Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk
Authors: Simpson RJ Jr, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A

Comparison of bleeding rates between statin and statin-free patients on warfarin: A claims database approach
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)
Authors: Guérin A, Hylek EM, Frois C, Barido DP, Marrone C, Bae J, Zhao Z

Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States
Authors: Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: Multiple versus single long-acting maintenance inhalers
Authors: Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P

Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the U.S.
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Korves C, Eldar-Lissai A, Rodermund D, Swallow KE, Cummings AK, Ariely R, Duh MS
Treatment persistence among atrial fibrillation/atrial flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting

Abstract: American Heart Association Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC, 12-14 May, 2011 (Poster)
Authors: Alpert JS, Guérin A, Lin J, Jhaveri M, Wu EQ

Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy

Abstract: AMCP 23rd Annual Meeting & Showcase, Minneapolis, MN, 27-29 April, 2011 (Poster)
Authors: Guérin A, Lin J, Jhaveri M, Wu EQ, Alpert J

Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy

Abstract: American College of Cardiology (ACC 2011) 60th Annual Scientific Sessions, New Orleans, LA, 2-5 April, 2011 (Poster)
Authors: Alpert JS, Guérin A, Lin J, Jhaveri M, Wu EQ

Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction


Incremental third-party costs associated with COPD exacerbations: A retrospective claims analysis

Authors: Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S

Copayment level, treatment persistence, and health care utilization in hypertension patients treated with single-pill combination therapy

Authors: Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP

Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: In U.S. patients with hypertension

Authors: Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ

Chronic thromboembolic pulmonary hypertension (CTEPH): Direct cost of illness in the U.S. privately insured population

Authors: Kirson NY, Bimbaum HG, Ivanova JI, Waldman T, Schiller M, Joish VN, Williamson T

Pulmonary arterial hypertension (PAH): Direct cost of illness in the U.S. privately insured population

Authors: Kirson NY, Bimbaum HG, Ivanova JI, Waldman T, Schiller M, Joish VN, Williamson T

Persistence with nebivolol compared to other β-blockers in the treatment of hypertension: A retrospective claims analysis

Authors: Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum S, Ramasamy A, Wu EQ

Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement

Authors: Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ

Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives

Publication: Curr Med Res Opin. 2010 Sep; 26(9):2065-76.
Authors: Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG
The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure

Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS

Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease

Authors: Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM

Hospitalization due to heart failure is associated with significant medical resource utilization and costs

Abstract: Quality of Care and Outcomes Research (QCOR) in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington D.C., 19-21 May, 2010 (Poster)
Authors: Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS

Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk

Abstract: Quality of Care and Outcomes Research (QCOR) in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington D.C., 19-21 May, 2010 (Poster)
Authors: Simpson Jr R, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A

Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in south central region

Abstract: ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)
Authors: Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ

Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis

Authors: Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP

Alikiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis

Authors: Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ

Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBs) in patients with hypertension

Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension

Authors: Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH

Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension

Authors: Simpson RJ Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A

Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs. simvastatin in an employed population

Authors: Simpson RJ Jr, Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A
Costs associated with cardiovascular events in patients with hypertension in U.S. managed care settings
Authors: Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH

Impact of single-photon emission computed tomography (SPECT) use after acute myocardial infarction (AMI) on cardiac procedure rates and hospital length of stay
Authors: Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ

The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS)
Authors: Crémieux PY, Fortin P, Meilleur MC, Montague T, Royer J

Antihypertensive drugs: A perspective on the value of improved blood pressure control in the U.S.
Authors: Long G, Cutler DM, Berndt ER

Productivity costs associated with cardiometabolic risk factor clusters in the United States
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO

Prevalence, referral patterns, testing, and surgery in aortic valve disease: Leaving women and elderly patients behind?
Authors: Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG

Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.
Authors: Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO

The value of antihypertensive drugs: A perspective on medical innovation

Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States
Authors: Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR

Economic burden and co-morbidities of atrial fibrillation in a privately insured population
Authors: Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population
Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

DERMATOLOGY

Healthcare costs in psoriasis patients newly initiated on a biologic therapy or methotrexate
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Zhang F, Hiscock R

Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alfa inhibitors versus methotrexate
Authors: Guerin A, Dea K

Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis
Authors: Signorovitch JE, Betts K, Yan S
Economic and comorbidity burden of moderate-to-severe psoriasis

**Abstract:** Winter Clinical Dermatology Conference, Kona, HI, January 17-22, 2014 (Poster)

**Abstract:** 10th Annual Maui Derm Conference, Maui, HI, January 26-30, 2014 (Poster)

**Authors:** Feldman S, Zhao Y, Tran MH, Shi L

Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study

**Publication:** J Eur Acad Dermatol Venereol. 2013 May 17. [Epub ahead of print]

**Authors:** Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM

Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology

**Abstract:** American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL, March 1-5, 2013.

**Authors:** Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE

Validation of the physician’s global assessment of psoriasis of the hands and/or feet as a clinical endpoint

**Abstract:** American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL (Poster)

**Authors:** Goldblum O, Sundaram M, Yang M, Thomason D

Validation of the hidradenitis suppurativa clinical response (HiSCR) as a clinical endpoint for hidradenitis suppurativa treatment evaluation

**Abstract:** American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL (Poster)

**Authors:** Okun MM, Sundaram M, Gu Y, Yang M

Sleep quality and other patient-reported outcomes improve after psoriasis patients with suboptimal response to other systemic therapies are switched to adalimumab: Results from PROGRESS, an open-label Phase IIIB trial

**Publication:** British Journal Dermatology. 2012 Dec; 167(6): 1374-81.

**Authors:** Strober BE, Sobell JM, Duffin KC, Bao Y, Guérin A, Yang H, Goldblum O, Okun MM, Mulani MP

Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in Germany

**Abstract:** 15th Annual ISPOR European Congress, Berlin, Germany, 3-7 November, 2012 (Poster)

**Authors:** Betts KA, Yan Y, Sundaram M, Hengst N, Wolff M, Bensimon AG

Risks of developing psychiatric disorders in pediatric patients with psoriasis


**Authors:** Kimball AB, Wu EQ, Guérin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM

Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event-free response versus etanercept

**Abstract:** 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, 27-30 September, 2012 (Poster)

**Authors:** Reich K, Signorovitch JE, Sundaram M, Mulani PM

Psoriasis is significantly associated with lower rates of pregnancy and live births

**Abstract:** 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, 27-30 September, 2012 (Poster)

**Authors:** Cather JC, Horn EJ, Sundaram M, Latremouille-Viau D, Guérin A

Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases

**Abstract:** 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, 27-30 September 2012 (Poster)

**Authors:** Sundaram M, Okun MM, Guérin A, Styles A, Hayes OA, Aberki C, Mulani PM

Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease

**Abstract:** 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, 27-30 September 2012 (Poster)

**Authors:** Kimball AB, Sundaram M, Samuelson TM, Signorovitch JE
Economic burden of hidradenitis suppurativa following a single surgical intervention: Assessment of unmet need using a retrospective claims-based analysis

Abstract: 21st European Academy of Dermatology and Venereology Congress 2012, Prague, Czech Republic, 27-30 September, 2012 (Poster)
Authors: Jemec G, Guérin A, Sundaram M, Kaminsky MS, Okun MM

Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, 27-30 September, 2012 (Poster)
Authors: Reich K, Sundaram M, Signorovitch J, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM

Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis

Abstract: 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic, 27-30 September, 2012 (Poster)
Authors: Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM

Treatment patterns in psoriasis patients newly initiated on an oral conventional systemic therapy or on phototherapy

Abstract: 21st EADV Congress, Prague, Czech Republic, September 27-30, 2012 (Presentation)
Authors: Zhang F, Guérin A, Hiscock R, Kimball A

Economic burden associated with workplace productivity losses (WPL) in patients with psoriasis in a US population

Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)
Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States

Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)
Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z

Economic burden of psoriasis (PSO) and obesity in patients with psoriasis in the United States

Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)
Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z

Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States

Abstract: 70th AAD Annual Meeting, San Diego, CA, 16-20 March, 2012 (Poster)
Authors: Guérin A, Gauthier G, Day R, Khan Z, Zhang F

Economic burden of psoriasis and obesity in patients with psoriasis in the United States

Abstract: ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)
Authors: Wu EQ, Guérin A, Latremouille-Viau D, Day R, Khan Z

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis

Authors: Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, and Mulani PM

Economic burden of psoriasis and diabetes in a population of patients with psoriasis in the United States

Abstract: 20th EADV Congress, Lisbon, Portugal, 20-24 October 2011 (Presentation) and the ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)
Authors: Wu EQ, Guérin A, Latremouille-Viau D, Gauthier G, Day R, Khan Z, Zhang F

Treatment patterns of psoriasis patients and trends over time

Abstract: ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)
Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z

Treatment patterns of psoriasis patients and trends over time

Abstract: 20th EADV Congress, Lisbon, Portugal, 20-24 October, 2011 (Poster)
Authors: Zhang F, Latremouille-Viau D, Gauthier G, Day R, Khan Z
Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis  
**Abstract:** Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, 4-8 February, 2011 (Poster)  
**Authors:** Papp K, Wu EQ, Goldblum OM, Gupta SR

Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis  
**Abstract:** Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, 4-8 February, 2011 (Poster)  
**Authors:** Wu EQ, Guérin A, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y

Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis  
**Abstract:** Academy of Dermatology (AAD) 69th Annual Meeting, New Orleans, LA, 4-8 February, 2011 (Poster)  
**Authors:** Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y

Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial  
**Authors:** Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM

Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: Analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials  
**Authors:** Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM

Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial  
**Authors:** Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life  
**Abstract:** Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  
**Authors:** Menter A, Signorovitch J, Parikh K, Yu AP, Wu EQ, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani PM

Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity  
**Abstract:** 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  
**Authors:** Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

Adalimumab provides health-related quality-of-life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy  
**Abstract:** 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  
**Authors:** Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM

Resource utilization and costs in patients with moderate to severe psoriasis with adalimumab or etanercept in a real-world setting  
**Abstract:** 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  
**Authors:** Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM
Effects of ABT-874 versus etanercept or placebo on health-related quality of life in patients with moderate to severe psoriasis  
*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  
*Authors:* Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P

Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy  
*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  

Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment  
*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  

Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy  
*Abstract:* 19th Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden, 6-10 October, 2010 (Poster)  

Comparative effectiveness without head-to-head trials: A method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept  
*Authors:* Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM

Economic burden of comorbidities in patients with psoriasis is substantial  
*Authors:* Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial  
*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P

Coronary heart disease and stroke risk in patients with psoriasis: Retrospective analysis  
*Authors:* Kimball AB, Guérin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P

Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparisons of adalimumab with etanercept, infliximab, and ustekinumab  
*Authors:* Signorovitch J, Mulani P, Gupta S, Bao Y

Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis  
*Authors:* Signorovitch J, Gupta SR, Bao Y, Mulani PM

Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder  
*Authors:* Wu EQ, Signorovitch JE, Bao Y, Mulani PM
Adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy: Effects on patient-reported outcomes in patients with psoriasis

Abstract: American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, FL, 5-9 March, 2010 (Poster)
Authors: Thaçi D, Xie J, Gupta SR, Mulani PM

Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder

Abstract: American Academy of Dermatology (AAD) 68th Annual Meeting, Miami Beach, FL, 5-9 March, 2010 (Poster)
Authors: Wu EQ, Signorovitch JE, Bao Y, Mulani PM

High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: Associated clinical and economic outcomes in real-world practice

Authors: Saurat JH, Guérin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM

Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: A pooled analysis of randomized clinical trials

Authors: Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM

Economic burden of psoriasis compared to the general population and stratified by disease severity

Authors: Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM

The impact of psoriasis on health care costs and patient work loss

Authors: Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G

The direct and indirect cost burden of atopic dermatitis: An employer-payer perspective

Authors: Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G

A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization

Authors: Fowler JF, Duh MS, Chang J, Person J, Thom D, Raut M, Ghosh A, Den E, Reynolds J

Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs

Authors: Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thom D, Person J, Duh MS

DIABETES

Units and costs per day per claim of comparable insulins supplied to Medicaid patients

Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Ivanova JI, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R

Burden of diabetic foot ulcers for Medicare and private insurers

Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB

Quality measure attainment in patients with type 2 diabetes mellitus

Authors: Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes

Authors: Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA
Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes


*Authors:* Virdi NS, Lefebvre P, Parisé H, Duh MS, Pilon D, Laliberté F, Sundaresan D, Garber L, Dirani R

Distribution of costs in patients with type 2 diabetes mellitus: a retrospective claims database analysis

*Abstract:* 49th Annual Meeting, September 23-27, 2013, Barcelona, Spain (Poster)


Cost predictors in type 2 diabetes mellitus: a retrospective claims database analysis

*Abstract:* 49th Annual Meeting, September 23-27, 2013, Barcelona, Spain (Poster)

*Authors:* Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guérin A, Samp J, Wu E

Relative and attributable diabetes risk associated with hyperuricemia in U.S. veterans with gout


*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L

Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes mellitus

*Publication:* Diabetes Care. 2013 June 25. [Epub Ahead of Print]

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA

Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in elderly vs. overall people living with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU)

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)

*Authors:* Lafeuille MH, Gravel J, Bailey R, Martin S, Garber L, Duh MS, Lefebvre P

Economic outcomes associated with HBA1C and LDL-C goal achievement in patients with type 2 diabetes mellitus

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca V

Healthcare resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)

*Authors:* Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep F, Birnbaum H

Trend in economic burden of diabetes in urban China from 2009 to 2011

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)

*Authors:* Wu EQ, Xie J, Du EX, Ming L, Liu G

Medical, drug, and work loss costs of diabetic foot ulcers

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Podium presentation)

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skomicki M, Parsons N

Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs


*Authors:* Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM

The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus

*Abstract:* 1st American Diabetes Association Middle East Congress, Dubai, UAE, 4-6 December, 2012 (Poster)

*Authors:* Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB

Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens verses vials

*Abstract:* ISPOR 15th Annual European Congress 2012, ICC Berlin, Germany, 6 November, 2012 (Poster)

*Authors:* Eby E, Frois C, Guérin A, Boggs J, Nyhuis A, Swindle R
Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients

Abstract: ISPOR 15th Annual European Congress 2012, ICC Berlin, Germany, 6 November, 2012 (Poster)
Authors: Eby E, Frois C, Guérin A, Boggs JA, Nyhuis A, Swindle R

HbA1c reduction associated with initial vs. sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM)

Abstract: 2012 ISPOR 15th Annual European Congress, ICC Berlin, Berlin, Germany, 3-7 November, 2012 (Poster)
Authors: Bron M, Chen KS, Ayyagari R, Sharma H, Wu EQ

Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus

Abstract: 48th EASD Annual Meeting, Berlin, Germany, 1-5 October, 2012 (Poster)
Authors: Chen KS, Wu EQ, Cheng D, Bensimon AG, Bron M

Outcomes associated with post-discharge insulin continuity in U.S. patients with type 2 diabetes mellitus initiating insulin in the hospital
Authors: Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T

Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4is) combination therapy: A subgroup analysis

Abstract: 5th ISPOR Asia-Pacific Conference, Taipei, Taiwan, 2-4 September, 2012 (Poster)
Authors: Bron M, Cheng D, Chen KS, Sharma H, Wu EQ

Comparison of clinical and economic outcomes associated with DPP-4 inhibitors (DPP-4i) versus sulfonylurea (SU) in combination with metformin (MET) or pioglitazone (PIO) for the treatment of type 2 diabetes mellitus (T2DM)

Abstract: 5th ISPOR Asia-Pacific Conference, Taipei, Taiwan, 2-4 September, 2012 (Poster)
Authors: Bensimon AG, Bron M, Wu EQ, Chen KS, Cheng D

Glycemic control and quality of life for patients with type 2 diabetes mellitus in China

Abstract: 5th ISPOR Asia-Pacific Conference, Taipei, Taiwan, 2-4 September, 2012 (Poster)
Authors: Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ

Economic burden of type 2 diabetes mellitus in China

Abstract: ISPOR 17th Annual International Meeting Poster Session, Washington, DC, 2-6 June, 2012 (Poster)

Health utility for patients with type 2 diabetes mellitus in China

Abstract: ISPOR 17th Annual International Meeting Poster Session, Washington, DC, 2-6 June, 2012 (Poster)
Authors: Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ

Hypoglycaemia and accident risk in people with type 2 diabetes treated with antidiabetes drugs without insulin

Abstract: Diabetes UK Professional Conference, Glasgow, UK, 7-9 March, 2012 (Poster)
Authors: Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu EQ

Outcomes associated with insulin therapy disruption after hospital discharge among us patients with type 2 diabetes who had used insulin prior to and during hospitalization
Authors: Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T

Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs
Authors: Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ

Comparative efficacy of vildagliptin and sitagliptin in Japnese patients with type 2 diabetes mellitus: A matching-adjusted indirect comparison of randomized trials
Authors: Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB
Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.
Abstract: IDF World Diabetes Congress, Dubai, United Arab Emirates, 4-8 December, 2011.
Authors: Bron M, Yang HY, Yu AP, Marynchenko M, Fan L

Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population
Authors: Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP

Hypoglycemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population
Authors: Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP

Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence
Abstract: 47th EASD Annual Meeting, Lisbon, Portugal, 12-16 September, 2011 (Poster)
Authors: Zhou S, Wu EQ, Yu AP, Lu M, Sharma H, Graf T

Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization
Abstract: ENDO 2011 Annual Meeting, Boston, MA, 4-7 June, 2011 (Poster)
Authors: Wu EQ, Zhou S, Yu AP, Lu M, Graf T
Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET)

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Lefebvre P, Sarda SP, Laliberté F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

Authors: Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ

Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes—an application of marginal structural models

Authors: Yu AP, Yu YF, Nichol MB

Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large U.S. managed care cohort

Authors: Bron M, Yu A, Marynchenko M, Sun SX, Yang H, Wu EQ

Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes

Authors: Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T

Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients

Authors: Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O

Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs

Abstract: Journal of Managed Care Pharmacy. 2010 Mar; 16(2):147. Academy of Managed Care Pharmacy (AMCP) 22nd Annual Meeting & Showcase, San Diego, CA, 7-10 April, 2010 (Poster)
Authors: Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ

Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysis

Authors: Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA

Direct and indirect costs among employees with diabetic retinopathy in the United States

Authors: Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: Analysis using claims, laboratory, and medical record data

Publication: Curr Med Res Opin. 2007 Sep; 23(9):2157-69.
Authors: Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A

Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France

Publication: Curr Med Res Opin. 2007 Sep; 23(9):2035-42.
Authors: Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S

Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain

Authors: Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S
Productivity and medical costs of diabetes in a large employer population
*Authors*: Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg PE

Identification of diabetes patients using claims data: An economic analysis
*Authors*: Summers KH, Leong SA, Birnbaum HG, Greenberg PE, Kemner JE, Ramsey S

**ENDOCRINOLOGY**

Systematic review of real-world evidence on treatment of acromegaly
*Abstract*: I CE ENDO, 21-23 June,2014, Chicago, IL (Poster) (forthcoming)
*Authors*: Nellesen D, Oh D, Zhang J, Truong H

Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s disease
*Publication*: European Journal of Endocrinology. 2014 (forthcoming)

Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients
*Authors*: Wu EQ, Mulani P, Farrell MH, Sleep D

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
*Authors*: Oh WK, Proctor K, Nakabayashi M, Evan C, Torney LK, Daskivich T, Antràs L, Smith M, Neary MP, Duh MS

**GASTROINTESTINAL DISORDERS**

Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada
*Abstract*: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)

A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation
*Authors*: Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT

Vitala™ continence control device vs. traditional pouch system: A comparison of health-related quality-of-life
*Authors*: Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J

Quality of life and life enjoyment: An analysis of end colostomy patients
*Authors*: Yan S, Yang M, Hoch J, van den Broek N, Xie J, Warusavitarne

Budgetary impact of linaclotide in the treatment of US adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC)
*Abstract*: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
*Authors*: Taylor DCA, Carson RT, Xie J, Dean J, Du EX, Sarocco P, Blum S

Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population
*Abstract*: AMCP 25th Annual Meeting & Expo, San Diego, CA, April 3-5, 2013 (Poster)
*Authors*: Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, Wu EQ
Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: A review of the literature from the past decade  
*Authors:* Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW

Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term vs. long-term imatinib (IM) adjuvant therapy - a chart review analysis  
*Abstract:* 2012 ASCO Quality of Care Symposium, San Diego, CA, November 30-December 1, 2012 (Poster)  

Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)  
*Authors:* Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, T Abreu M

Cost-effectiveness of adalimumab for treatment of Crohn’s disease in Germany  
*Abstract:* International Society of Pharmacoeconomics and Outcome Research 15th Annual European Conference, 3-7 November, 2012, Berlin, Germany  
*Authors:* Yang M, Yang M, Skup M, Zhou ZY, Hengst N, Wolff M, Mulani PM, Chao J

Cost-effectiveness model of adalimumab for the treatment of moderate to severe ulcerative colitis in the United Kingdom  
*Authors:* Ali T, Yang M, Skup M, Yang M, Wu EQ, Chao J, Mulani PM

Prevalence and risk of developing gastrointestinal conditions in patients with chronic constipation  
*Abstract:* ACG Annual Scientific Meeting, Las Vegas, NV, 19-24 October, 2012 (Poster)  

Direct and indirect utilization and costs associated with ulcerative colitis  
*Authors:* Cohen RD, Rizzo J, Yang M, Diener M, Yang M, Skup M, Mulani PM, Chao J

Prevalence and risk of developing non-gastrointestinal physical and mental comorbidities in patients with chronic constipation  
*Abstract:* ACG Annual Scientific Meeting, Las Vegas, NV, 19-24 October, 2012 (Poster)  

Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation  
*Abstract:* ACG Annual Scientific Meeting, Las Vegas, NV, 19-24 October, 2012 (Poster)  

Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy  
*Abstract:* ACG Annual Scientific Meeting, Las Vegas NV, 19-24 October, 2012 (Poster)  
*Authors:* Colombel JF, Thakkar R, Robinson A, Yang M, Skup M, Swallow E, Betts KA, Chao JD, Mulani PM

Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis  

The economic burden of unmet treatment needs in Medicaid patients with chronic constipation  
*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)  
*Authors:* Carson RT, Guérin A, Lewis B, Yin D, Ramakrishnan K, Kaminsky MS, Wu EQ
Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis


Treatment patterns and indicators of unmet needs in Medicaid patients with irritable bowel syndrome with constipation and chronic constipation

Abstract: Digestive Disease Week, San Diego, California, 19-22 May, 2012 (Poster)
Authors: Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ

The economic burden of treatment failure in Medicaid patients with irritable bowel syndrome with constipation

Abstract: AMCP 24th Annual Meeting & Expo, San Francisco, California, 18-20 April, 2012 (Poster)
Authors: Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ

Assessing preference for deep remission in patients with Crohn’s disease

Abstract: European Crohn’s and Colitis Organisation (ECCO) 7th Congress, Barcelona, Spain, 16-18 February, 2012

Development of three practical indices for mucosal healing among patients with moderate to severe Crohn’s disease

Abstract: Inflammatory Bowel Diseases 2012, 7th Congress of ECCO-European Crohn’s and Colitis Organisation, Barcelona, Spain, 16-18 February, 2012 (Presentation)
Authors: Sandborn WJ, Panaccione R, Colombel J-F, Louis E, Yang M, Thakkar R, Chao J, Mulani PM

Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE

Abstract: Inflammatory Bowel Diseases 2012, 7th Congress of ECCO European Crohn’s and Colitis Organisation, Barcelona, Spain, 16-18 February, 2012 (Poster)

A retrospective comparison of health care outcomes in Crohn’s disease patients with and without prolonged steroid monotherapy

Abstract: 19th United European Gastroenterology Week, Stockholm, Sweden, 22–26 October, 2011 (Poster)
Authors: Siegel CA, Yang HY, Yu AP, Yang M, Mulani PM, Chao J

Increased risks of developing anxiety and depression in young patients with Crohn’s disease

Authors: Loftus EV Jr, Guérin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM

The economic and quality of life burden of illness in chronic constipation (CC) and irritable bowel syndrome (IBS): A systematic review

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Yee K, Nellesen D, Chawla A, Carson R, Lewis B

The CHOICE trial: Adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn’s disease who failed prior infliximab therapy

Authors: Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD

Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis

Abstract: 24th North American Cystic Fibrosis Conference, Baltimore, MD, October 21-23, 2010 (Poster)
Authors: Sawicki GS, Signorovitch J, Latremouille-Viau D, von Wartburg M, Wu EQ, Zhang J, Shi L
Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)

**Abstract:** American College of Gastroenterology Annual Scientific Meeting, San Antonio, TX, 15-20 October, 2010 (Poster)

**Authors:** Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M

Racial differences in use of biologics for Crohn's disease in a Medicaid population

**Abstract:** American College of Gastroenterology Annual Scientific Meeting, San Antonio, TX, 15-20 October, 2010 (Poster)

**Authors:** Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R

Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease

**Publication:** Inflamm Bowel Dis. 2010 Jun 1.

**Authors:** Loftus EV Jr, Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J

Systematic review: The costs of ulcerative colitis in western countries

**Publication:** Aliment Pharmacol Ther. 2010 Apr; 31(7):693-707.

**Authors:** Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease

**Publication:** Pharmacoeconomics. 2009; 27(7):693-7.07.

**Authors:** Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease


**Authors:** Loftus EV Jr, Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM

Impact of compliance with proton pump inhibitors on NSAID treatment


**Authors:** Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial


**Authors:** Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM

The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease


**Authors:** Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS

Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial

**Publication:** Am J Gastroenterol. 2008 Dec; 103(12):3132-41.

**Authors:** Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani PM

Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: Results from the CHARM study


Loss of treatment response to infliximab maintenance therapy in Crohn's disease: A payer perspective


**Authors:** Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF

The costs of Crohn's disease in the United States and other Western countries: A systematic review


**Authors:** Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J
Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: Development and validation
*Authors:* Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole J A, Cook SF, Walker AM

Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors
*Publication:* Dig Dis Sci. 2006 May; 51(5):877-84.
*Authors:* Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH

Computerized algorithms for the identification of irritable bowel syndrome, colonic ischemia, and complications of constipation: Validation through medical records
*Authors:* Sands BE, Duh MS, Ajene A, Walker AM

The economic consequences of irritable bowel syndrome: A U.S. employer perspective
*Authors:* Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ

**HEMATOLOGY**

Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R

High cost patients and cost patterns from pediatric to adult care in a Medicaid population with sickle cell disease
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Blinder M, Sasane M, Fortier J, Paley C, Duh MS, Vekeman F

High utilizers of healthcare resources: Results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)

Associations between clinical outcomes, healthcare resources utilization, and quality of life among patients with severe hemophilia A
*Abstract:* WHF Annual Conference, Melbourne, Australia, May 11-15, 2014 (Poster)
*Authors:* Lin P, Du E, Kelkar S, Xie J

Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism
*Authors:* Laliberté F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS

Risk of venous thromboembolism complications associated with recurrent venous thromboembolism
*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S

All-cause and disease-related costs associated with recurrent venous thromboembolism
*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S

Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12-Month complete cytogenetic response failure: A chart review analysis
*Abstract:* 54th ASH Annual Meeting and Exposition. Atlanta, GA, 8-11 December, 2012 (Poster)
*Authors:* DeAngelo DJ, Chen L, Guérin A, Styles A, Giguere-Duval P, Aberki C, Wu E
Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD)

**Abstract:** Value in Health. 2010 May; 13(3):A212. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)

**Authors:** Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS

Comparison of healthcare resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML)

**Abstract:** Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)

**Authors:** Wu EQ, Bolu V, Guo A, Guérin A, Tsaneva M, Williams D, Griffin J D

Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on healthcare resource utilization and costs

**Abstract:** Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)

**Authors:** Guérin A, Bolu V, Guo A, Wu EQ, Yu AP, Sirulnik LA, Griffin J D

Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab

**Abstract:** Value in Health. 2010 May; 13(3):A32. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)

**Authors:** Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS

Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study

**Abstract:** Value in Health. 2010 May; 13(3):A33. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)

**Authors:** Guérin A, Bolu V, Williams D

Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States

**Abstract:** Value in Health. 2010 May; 13(3):A210. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)

**Authors:** Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine DL, Garrison L

Red blood cell transfusions and the risk of ARDS among critically ill: A cohort study

**Publication:** Crit Care 2007 Jun 6; 11 (3): R63.

**Authors:** Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF

MENTAL HEALTH

Factors associated with performance on the Medicaid HEDIS measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia

**Abstract:** ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)

**Authors:** Lefebvre P, Pesa JA, Clancy Z, Fastenau J, Durkin M

Treatment patterns of patients receiving paliperidon palmitate in an inpatient setting

**Abstract:** ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)

**Authors:** Lefebvre P, Fortier J, Grittner AM, Muser E, Fastenau J, Duh MS, Lefebvre P

Comparison of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidon palmitate or oral antipsychotics in an inpatient setting

**Abstract:** ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)

**Authors:** Lefebvre P, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P

Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective

**Abstract:** APA 167th Annual Meeting, New York City, NY, 3-7 May, 2014 (Poster)

**Authors:** Signorovitch J, Wu E, Li N, Chopra P
Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective

Abstract: APA 167th Annual Meeting, New York City, NY, 3-7 May, 2014 (Poster)
Authors: Signorovitch J, Wu E, Li N, Chopra P

Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia

Publication: Curr Med Res Opin. 2014 April 15.
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Lefebvre P, Lafaille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Cloutier M

Burden of schizophrenia on selected comorbidity costs

Authors: Lafaille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P

The effectiveness of hydrotherapy in the treatment of social and behavioral aspects of children with autism spectrum disorders: A systematic review

Publication: J Multidiscip Healthc. 2014 Feb 3; 7:93-104.
Authors: Mortimer R, Privopoulos M, Kumar S

Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents: Applying matching-adjusted indirect comparison methodology


Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

Authors: Lafaille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS

Treatment persistence in attention deficit/ hyperactivity disorder: A retrospective analysis of patients initiated on lisdexamfetamine versus other medications


Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: A retrospective database analysis

Authors: Lafaille MH, Laliberté-Augé F, Lefebvre P, Frois C, Fastenau J, Duh MS

Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: A retrospective database analysis

[Epub ahead of print]
Authors: Lafaille MH, Laliberté-Augé F, Lefebvre P, Frois C, Fastenau J, Duh MS

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics

Publication: J Med Econ. 2013 Sep 5. [Epub ahead of print]
Authors: Lafaille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS

Treatment persistence in attention deficit/ hyperactivity disorder: A retrospective analysis of patients initiated on lisdexamfetamine versus other medications

Publication: J Med Econ. 2013 Sep 4. [Epub ahead of print]
Authors: Setyawan J, Guérin A, Hodgkins P, Gauthier G, Cloutier M, Wu EQ, Erder MH

Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults

Publication: J Med Econ. 2013 Aug 23. [Epub ahead of print]
Authors: Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu EQ, Erder MH
Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents: Applying matching-adjusted indirect comparison methodology
Publication: CNS Drugs. 2013 Aug 23. [Epub ahead of print]

Pre-diagnosis excess acute care costs in Alzheimer’s patients among a U.S. Medicaid population
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN

Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/ hyperactivity disorder: A retrospective analysis
Authors: Setyawan J, Hodgkins P, Guérin A, Gauthier G, Cloutier M, Wu EQ, Erder HM

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: Synthesizing results across different research designs
Authors: Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ

Impact of atypical antipsychotic use among adolescents with attention deficit/ hyperactivity disorder

Authors’ reply to Alatorre et al.: “Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/ hyperactivity disorder: application of a matching-adjusted indirect comparison”
Authors: Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V

Burden of schizophrenia on selected comorbidities costs
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Podium presentation)
Authors: Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P

Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R

Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS

Implications of early treatment among Medicaid patients with Alzheimer’s disease
Publication: Alzheimers Dement. 2013 May 2. [Epub ahead of print]
Authors: Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN

Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics
Publication: J Manag Care Pharm. 2012; 18(9):676-89.
Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Dammerman R, Erder MH, Wu EQ
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/ hyperactivity disorder: Application of a matching-adjusted indirect comparison
Authors: Erder MH, Xie J, Signorovitch JE, Chen KS, Hodkins PS, Lu M, Wu EQ and Sikirica V

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. non-antipsychotics
Abstract: Institute of Psychiatric Services Meeting in New York, NY, 4-7 October, 2012 (Poster)
Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH

Period prevalence of stimulant augmentation among pediatric attention deficit/ hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population
Authors: Sikirica V, DiBello J, Betts KA, Hodkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, Wu EQ

Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents
Authors: Sikirica V, Erder MH, Xie J, Macaulay M, Diener M, Hodkins P, Wu EQ

Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/ hyperactivity disorder (ADHD): A retrospective claims analysis
Authors: Setyawan J, Hodkins P, Wu E; Guérin A, Gauthier G, Cloutier M, Erder H

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: Results from a systematic literature review
Authors: Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH

Treatment patterns, resource utilization, and costs associated with guanfacine immediate release vs. guanfacine extended release among children and adolescents with attention-deficit/ hyperactivity disorder (ADHD)
Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)
Authors: DiBello J, Sikirica V, Samuelson TM, Xie J, He TL, Erder MH

Comparison of deviation rates from the labeled daily average consumption in patients initiated on stimulant medication for the treatment of attention-deficit/ hyperactivity disorder
Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)
Authors: Setyawan J, Hodkins PS, Guérin A Gauthier G, Cloutier M, Wu EQ, Erder MH

Comparative effectiveness research using matching-adjusted indirect comparison: An application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/ hyperactivity disorder and comorbid oppositional defiant disorder
Authors: Signorovitch JE, Erder MH, Xie J, Sikirica V, Lu M, Hodkins PS, Wu EQ

A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. non-antipsychotics
Abstract: 165th APA Annual Meeting, Philadelphia, PA, 5-9 May, 2012 (Poster)
Authors: Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH
Atypical antipsychotics vs. non-antipsychotics: Comparative treatment patterns, resource utilization and costs in stimulant-treated adolescents with ADHD who require subsequent pharmacotherapy
Abstract: AMCP 24th Annual Meeting & Expo, San Francisco, CA, 18-20 April, 2012 (Poster)
Authors: Sikirica V, Pliszka SR, Betts KA, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Erder MH, Wu EQ

Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a Medicaid population
Authors: Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH

Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention-deficit/ hyperactivity disorder: A retrospective study
Authors: Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH

Cost-effectiveness of guanfacine extended-release as an adjunctive therapy to a psychostimulant compared to psychostimulant monotherapy for the treatment of attention-deficit/ hyperactivity disorder in children and adolescents
Abstract: ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)
Authors: Sikirica V, Erder MH, Xie J, Macaulay D, Diener M, Hodgkins PS, Wu EQ

Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs
Authors: Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH
Urgent care utilization for adolescents treated with atypical antipsychotics or non-antipsychotics: A comparison of rates and reasons.

Abstract: 165th APA Annual Meeting, Philadelphia, PA, 5-9 May, 2012 (Poster)

Authors: Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH

Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change


Remission of major depressive disorder without adverse events: A comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors


Authors: Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Haim Erder M

Comparison of real-world healthcare costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)

Authors: Swindle R, Ivanova JI, Birnbaum HG, Cumming AK, Kantor E, Schiller M, Clark T, Reed C

The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention deficit/ hyperactivity disorder (ADHD) in children and adolescents

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)

Authors: Erder MH, Xie J, Chen K, Wu E, Hodgkins P, Sikirica V

Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder


Authors: Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH

Perceptions and prescribing considerations among U.S. psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics

Publication: Curr Med Res Opin. 2010 Dec; 26(12):2735-44.

Authors: Frois C, Guérin A, Saraogi A, Panish J, Dirani R

Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: A 6-month retrospective study


Authors: Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM

Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil


Authors: Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahlers KH, Duh MS

Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States


Authors: Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Crémioux PY, Greenberg PE

Employer burden of mild, moderate, and severe major depressive disorder: Mental health services utilization and costs, and work performance

Publication: Depress Anxiety. 2010; 27(1):78-89.

Authors: Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE

Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder


Authors: Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD
Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%
Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH

Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin
Authors: Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH

Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons
Authors: Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A

Cost of illness of post-traumatic stress disorder compared with major depressive disorder
Authors: Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G

The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trial
Authors: Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P

Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: Results from the WHO World Mental Health Survey Initiative
Publication: Depress Anxiety. 2010 Apr; 27(4):351-64.

Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States
Authors: Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Crémieux PY, Greenberg PE

Determinants of direct cost differences among U.S. employees with major depressive disorders using antidepressants
Authors: Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Grobellet CR

Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia
Publication: J Pain. 2009 Sep; 10(9):976-83.
Authors: White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG

Treatment persistence, healthcare utilization and costs in adult patients with major depressive disorder: A comparison between escitalopram and other SSRI/SNRIs
Authors: Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH

Antidepressant treatment patterns and costs among U.S. employees
Authors: Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R

Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population
Authors: Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G

Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population
Authors: Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G
Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/ SNRI antidepressants

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu A, Ben-Hamadi R, Erder MH

Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu AP, Erder MH

Health care costs of adults treated for attention-deficit/ hyperactivity disorder who received alternative drug therapies

*Publication:* J Manag Care Pharm. 2007 Sep; 13(7):561-9.
*Authors:* Wu EQ, Birnbaum HG, Zhang HF

Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication

*Publication:* Arch Gen Psychiatry. 2007 May; 64(5):543-52.
*Authors:* Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC

Considering the costs of bipolar depression

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum HG, Greenberg PE, Hirschfeld RM, Wang PS

Annual prevalence of diagnosed schizophrenia in the U.S.A: A claims data analysis approach

*Authors:* Wu EQ, Shi L, Birnbaum HG, Hudson T, Kessler RC

Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers


The economic burden of depression in the U.S.: Societal and patient perspectives

*Authors:* Greenberg PE, Birnbaum HG

The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R)


The economic burden of schizophrenia in the United States in 2002

*Authors:* Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Mouls M, Aggarwal J

The prevalence and effects of adult attention deficit/ hyperactivity disorder on work performance in a nationally representative sample of workers

*Authors:* Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum HG, Greenberg PE, Johnston JA, Spencer T, Ustun TB

Costs of attention deficit-hyperactivity disorder (ADHD) in the U.S.: Excess costs of persons with ADHD and their family members in 2000

*Authors:* Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR

Economic implications of treatment-resistant depression among employees

*Authors:* Greenberg PE, Corey-Lisle PK, Birnbaum HG, Marynchenko M, Claxton A

What’s so different about anxiety disorders (such as phobias)?

*Authors:* Greenberg PE, Birnbaum HG, Sisitsky T
Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients
Authors: Swensen A, Birnbaum HG, Ben-Hamadi R, Greenberg PE, Crémieux PY, Secnik K

Depression and fibromyalgia: Treatment and cost when diagnosed separately or concurrently
Authors: Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F

Money can’t buy happiness...
Publication: Business & Health. 2004 April 15.
Authors: Greenberg PE, Birnbaum HG, Kessler RC

The economic burden of depression with painful symptoms
Authors: Greenberg PE, Leong SA, Birnbaum HG, Robinson RL

Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: A pilot study
Authors: Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Dube S

The economic burden of depression in the United States: How did it change between 1990 and 2000?
Authors: Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK

Attention-deficit/hyperactivity disorder: Increased costs for patients and their families
Authors: Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg PE, Claxton A

Economic consequences of not recognizing bipolar disorder patients: A cross-sectional descriptive analysis
Authors: Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA

The economics of women and depression: An employer’s perspective
Authors: Birnbaum HG, Leong SA, Greenberg PE

The economic burden of anxiety and stress disorders
Authors: Kessler RC, Greenberg PE

Identification of a claims data “signature” and economic consequences for treatment-resistant depression
Authors: Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ

An analysis of the diffusion of new antidepressants: Variety, quality, and marketing efforts
Authors: Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T

Cost of depression: Current assessment and future directions
Authors: Greenberg PE, Leong S, Birnbaum HG

Measuring Alzheimer’s disease progression with transition probabilities: Estimates from CERAD

Assessing the economic impact of psychiatric disorders: Where to begin?
Authors: Greenberg PE, Leong SA, Birnbaum HG

Depression and work productivity: The comparative costs of treatment versus nontreatment
Authors: Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC
The workplace burden of depression: Underlying causes, recent empirical findings, and future directions
Authors: Greenberg PE, Birnbaum HG

Management of major depression in the workplace: Impact on employee work loss
Authors: Kessler R, Birnbaum HG, Crémieux PY, Greenberg PE

The impact of antidepressant use on social functioning: Reboxetine versus fluoxetine
Authors: Venditti LN, Arcelus A, Birnbaum HG, Greenberg PE, Barr CE, Rowland C, Williamson T

Workplace burden of depression: Case study in social functioning using employer claims data
Authors: Birnbaum HG, Greenberg PE, Barton M, Kessler RC, Rowland C, Williamson T

Depression in the workplace: Effects on short-term disability
Authors: Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P

The economic burden of anxiety disorders in the 1990s
Authors: Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ

Workplace performance effects from chronic depression and its treatment

Improvement in subjective work performance after treatment of chronic depression: Some preliminary results. Chronic depression study group
Authors: Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB

Depression in the workplace: An economic perspective
Authors: Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER

Depression: A neglected major illness
Authors: Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER

The economic burden of depression in 1990
Authors: Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER

MUSCULOSKELETAL DISEASE

Effect of improving adherence to disease-modifying agents on healthcare resource utilization and medical costs in patients with multiple sclerosis
Abstract: ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
Authors: Yermakov S, Davis M, Calnan M, Fay M, Duh M, Iyer R

Direct and indirect cost burden associated with multiple sclerosis relapses: Excess costs of persons with MS and their spouse caregivers
Authors: Parisé H, Laliberté F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B

Relationship between adherence to disease-modifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis
Abstract: 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16 2011 (Poster)
Authors: Philips AL, Ivanova J, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM
Real-world use of duloxetine for low back pain and chronic low back pain: Treatment patterns, direct and indirect costs

Authors: Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R

The cost of disability and medically related absenteeism among employees with multiple sclerosis in the U.S.
Authors: Ivanova JI, Birnbaum HG, Samuels S, Davis M, Crémieux PY, Phillips AL, Meletiche D

Economic impact of multiple sclerosis disease-modifying drugs in an employed population: Direct and indirect costs
Authors: Birnbaum HG, Ivanova JI, Samuels S, Davis M, Crémieux PY, Phillips AL, Meletiche D

Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance
Authors: Meadows ES, Rousculp M, Sasser AC, Birnbaum HG, Moyneur E, Mallet D, Johnston JA

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population
Authors: Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment
Authors: Duh MS, Shepard Mj, Wilberger J, Bracken MB

NEPHROLOGY

Serum urate and incidence of kidney disease among veterans with gout
Publication: J Rheumatology. 2013 May. [Epub Ahead of Print]
Authors: Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk RH, Liu J, Shi L

Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Lafeuille MH, Bailey RA, Senbeta M, McKenzie RS, Lefebvre P

Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease
Authors: Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbeta M, Piech CT, Lefebvre

Erythropoiesis-stimulating agents utilization and costs in patients with chronic kidney disease not on dialysis from two large claims databases
Authors: Lafeuille MH, Bailey RA, Laliberté F, Senbeta M, Blacksmith A, Lefebvre P

Seven year trends of pharmacy benefit erythropoiesis-stimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis
Authors: Vekeman F, Bailey RA, Laliberté F, Senbeta M, McKenzie RS, Lefebvre P

Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis
Authors: Lafeuille MH, Bailey RA, Laliberté F, Senbeta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P
Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis


*Authors:* Lafeuille MH, Bailey RA, Laliberté F, Senbeta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P

---

**Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients**


*Authors:* Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT

---

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: A managed care perspective**


*Authors:* Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P

---

**The economic impact of pre-dialysis epoetin alfa on health care and work loss costs in chronic kidney disease: An employer's perspective**


*Authors:* Moynére E, Bookhart BK, Mody SH, Fournier AA, Mallet D, Duh MS

---

**Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer's perspective**


*Authors:* Moynére E, Bookhart BK, Mody SH, Fournier A, Mallet D, Duh MS

---

**Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease**


*Authors:* Einarson T, Machado M, Walker J, Iskedjian M, Crémi eux PY, Van Audenrode M, Lefebvre P

---

**The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease**


*Authors:* Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT

---

**Interstitial cystitis: Cost, treatment and comorbidities in an employed population**


*Authors:* Wu EQ, Birnbaum HG, Mareva M, Parece A, Huang Z, Mallett D, Taitel H

---

**Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organizations**

*Publication:* Drugs Aging. 2006; 23(12):969-76.

*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT

---

**The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease**


*Authors:* Crémi eux PY, Van Audenrode M, Lefebvre P

---

**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations**


*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Piech CT

---

**A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis**


*Authors:* Wu EQ, Birnbaum HG, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ

---

**Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy**

*Publication:* J of Urology 2006 Jan; 175(1):136-9; discussion 139.

*Authors:* Smith MR, Boyce SP, Moynére E, Duh MS, Raut M, Brandman J

---

**Employees with overactive bladder: Work loss burden**


*Authors:* Wu EQ, Birnbaum HG, Marynchenko M, Mareva M, Williamson T, Mallett D
Cost of stress urinary incontinence: A claims data analysis
*Authors:* Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P

Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis
*Publication:* Pharmacotherapy. 2003 May; 23(5):690-3.
*Authors:* Barnett AL, Crémieux PY

Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts
*Authors:* Duh MS, Walker AM, Kronlund KH Jr

Prediction and cross-validation in modeling incident cases of hepatic disorders using automated medical data
*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K

NEUROLOGICAL DISORDERS

The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs

Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: a longitudinal analysis

Costs of Parkinson’s disease in a privately insured population
*Publication:* Pharmacoeconomics. 2013 Sep; 31(9):799-806.
*Authors:* Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD

An economic model of Parkinson’s disease: Implications for slowing progression in the United States
*Authors:* Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the U.S.
*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM

Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy
*Authors:* Helmers SL, Duh MS, Guérin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E

Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization

Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson’s disease
*Authors:* Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD

Early retirement and income loss in patients with early and advanced Parkinson’s disease
*Publication:* Appl Health Econ Health Policy. 2011 Nov 1; 9(6):367-76.
*Authors:* Johnson S, Davis M, Kaltenboeck A, Birnbaum HG, Grubb E, Tarrants M, Siderowf A.
Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy

*Authors:* Helmers SL, Duh MS, Guérin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E

Uncontrolled epilepsy in a Medicaid population

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)

Assessment of Parkinson's disease progression rates by stage of disease

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
*Authors:* Johnson SJ, Kaltenboeck A, Diener MD, Tarrants ML, Birnbaum HG

Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
*Authors:* Duh MS, Faught E, Guérin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD

Burden of uncontrolled epilepsy in a privately-insured population

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI, April 9-16 2011 (Poster)
*Authors:* Manjunath R, Faught E, Paradis PE, Parisé H, Lafeuille MH, Lefebvre P, Duh MS

Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine

*Publication:* Cephalalgia. 2011 Feb; 31(3):357-367.
*Authors:* Yang M, Rendas-Baum R, Varon SF, Kosinski M

Economic burden of epilepsy among the privately insured in the U.S.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S

Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S

Generic antiepileptic drugs and associated medical resource utilization in the United States


Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis

*Authors:* Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM

Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with post herpetic neuralgia

*Abstract:* Value in Health. 2010 May; 13(3):A206. ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster); Journal of Managed Care Pharmacy. 2010 Mar; 16(2):149. Academy of Managed Care Pharmacy (AMCP) 22nd Annual Meeting & Showcase, San Diego, CA, 7-10 April, 2010 (Poster)
*Authors:* Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K

Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%

Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis

*Abstract:* 62nd American Academy of Neurology (AAN) Annual Meeting, Toronto, Ontario, Canada, 10-17 April, 2010 (Poster)

*Authors:* Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D

---

The economic implications of generic substitution of antiepileptic drugs: A review of recent evidence


*Authors:* Duh MS, Cahill KE, Paradis PE, Crémieux PY, Greenberg PE

---

Impact of nonadherence to antiepileptic drugs on health care utilization and costs: Findings from the RANSOM study


*Authors:* Faught RE, Weiner JR, Guérin A, Cunnington MC, Duh MS

---

Nonadherence to antiepileptic drugs and increased mortality: Findings from the RANSOM study


*Authors:* Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC

---

Interpretation of the weight matrix in an artificial neural network


*Authors:* Duh MS, Walker AM, Ayanian JZ

---

Epidemiologic interpretation of artificial neural networks


*Authors:* Duh MS, Walker AM, Ayanian JZ

---

Prediction and cross-validation of neural networks versus logistic regression: Using hepatic disorders as an example


*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K

---

The effectiveness of surgery on the treatment of acute spinal cord injury and its relationship with pharmacological treatment


*Authors:* Duh MS, Shepard MJ, Wilberger JE, Bracken MB

---

OBESITY, METABOLIC, AND NUTRITIONAL DISORDERS

The impact of bariatric surgery on comorbidities and medication use among obese patients


*Authors:* Crémieux PY, Ledoux S, Clerici C, Crémieux F, Buessing M

---

Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes


*Authors:* Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T

---

ONCOLOGY

Treatment and survival patterns among ALK+NSCLC patients following crizotinib discontinuation

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)


---

Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation

*Publication:* Alimentary Pharmacology & Therapeutics (forthcoming)


---

Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012


*Authors:* Swallow E, Zhang J, Thomason D, Ruó-Ding T, Kageleiry A, Signorovitch J
Description of ALK+ NSCLC patient characteristics and ALK testing patterns

Abstract: 2014 ASCO Annual Meeting, Chicago, IL, 30-3 June, 2014 (Poster)

Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting

Abstract: 2014 ASCO Annual Meeting, Chicago, IL, 30-3 June, 2014 (Poster)

Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC


Impact of underestimation of risk on treatment duration and recurrence in GIST patients

Abstract: 2014 ASCO Annual Meeting, Chicago, IL, 30-3 June, 2014 (Poster)
Authors: Guerin A, Conley AP, Huang Q, Sasane M, Wu EQ, Macalalad AR, Keir CH, Schwiep F

Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis

Authors: Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L

Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia

Authors: Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL

Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review


Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison

Authors: Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.

Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: A U.S. medical record review


Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: A chart review analysis

Authors: Deangelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ

Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data

Authors: Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW

Costs associated with intravenous cancer therapy administration in patients with metastatic soft tissue sarcoma in a U.S. population

Authors: Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Kamer P, Wong B
Multi-center experience with CELLSEARCH circulating tumor cell kit on patients with metastatic breast cancer
Abstract: SABSC, San Antonio, TX, December 10-14, 2013 (Poster)
Authors: Montero J, Eapen S, Tran K, Adler P, Gorin B

Assessing the impact of substandard copy medicines in developing countries: The experience with imatinib copies
Authors: Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L

Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase
Authors: Guérin A, Chen L, Wu EQ, Dea K, Goldberg S

Study of imatinib treatment patterns and outcomes among U.S. veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia
Authors: Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L

Association between molecular monitoring and long term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
Authors: Goldberg SL, Chen L, Guérin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ

Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib
Publication: Curr Med Res Opin. 2013 Sep;29 (9):1075-82.
Authors: Goldberg SL, Chen L, Guérin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ

Clinical predictors of survival in men with castration-resistant prostate cancer: Evidence that Gleason score 6 cancer can evolve to lethal disease
Authors: Nakabayashi M, Hayes J, Taplin ME, LeFebvre P, Lefaiville MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW

Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data
Authors: Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW

Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
Authors: Castellano D, Duh MS, Korves C, Suthoff ED, Neary M, Hernández Pastor LJ, Bellmunt J

Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy: A retrospective chart extract-based approach
Authors: Conley AP, Guérin A, Sasane M, Gauthier G, Schwiep F, Keir CH and Wu EQ

Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib - a retrospective chart review analysis
Authors: Griffin JD, Guérin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ
Study of imatinib treatment patterns and outcomes among U.S. veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia

Publication: J Oncol Pract. 2013 May. [Epub Ahead of Print]
Authors: Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L

Observed abiraterone acetate (ZYTIGA) utilization by prostate cancer patients in a large U.S. administrative claims database

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Lefauleille MH, Dean J, Lefebvre P, Ellis L, Senbetta M

Healthcare resource utilization and cost of Medicare patients with non-small cell lung cancer (NSCLC)

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Yenikomshian MA, Hackshaw MD, Cai X, Trahey A, Arondekar B, Knoll S, Duh MS

Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM)

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Knopf K, Duh MS, Lefauleille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo R

Incremental cost of brain metastases among patients with metastatic melanoma

Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS

Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer

Authors: Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment

Authors: Garrison LP Jr, Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS

Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States

Authors: Xie J, Diener M, Gourab De, Yang H, Wu EQ and Namjoshi M

Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung and head and neck cancers with epidermal growth factor receptor inhibitors

Authors: Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guérin A

Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey

Abstract: 54th ASH Annual Meeting and Exposition, Atlanta, GA, 8-11 Dec, 2012 (Poster)
Authors: Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guérin A, Liu NS, Kaminsky MS, Wu EQ

Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy

Abstract: 54th ASH Annual Meeting and Exposition, Atlanta, GA, 8-11 Dec, 2012 (Poster)
Authors: Griffin JD, Chen L, Guérin A, Macalalad AR, Luo J, Wu EQ
Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy

Abstract: 54th ASH Annual Meeting and Exposition, Atlanta, GA, 8-11 Dec, 2012 (Poster)

Authors: Griffin JD, Chen L, Guérin A, Macalalad AR, Luo J, Wu EQ

Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib

Abstract: 54th ASH Annual Meeting and Exposition, Atlanta, GA, 8-11 Dec, 2012 (Poster)

Authors: Griffin JD, Chen L, Guérin A, Macalalad AR, Luo J, Wu EQ

Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study


Authors: Choueiri TK, McDermott D, Duh MS, Sarda SP, Neary MP, Oh WK

Comprehensive investigation of adverse event (age)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies

Abstract: ISPOR 15th Annual European Congress, ICC Berlin, Germany, 6 November, 2012 (Poster)

Authors: Hurvitz SA, Guérin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: A chart review analysis

Publication: Curr Med Res Opin. Epub date 2012 Nov 5.

Authors: Chen L, Guérin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP)

Abstract: ESH-iCML International Conference, Baltimore, MD, 20-23 September, 2012 (Poster)

Authors: Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L

Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases


Authors: Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M

The economic burden of metastatic breast cancer: A U.S. managed care perspective


Authors: Montero AJ, Eapen S, Gorin B, Adler P

A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting


Authors: Guérin A, Chen L, Wu EQ, Ponce de Leon D, Griffin J D

Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia


Authors: Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: Evidence from U.S. community oncology clinics


Authors: Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS

Comprehensive investigation of adverse event (age)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies

Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)

Authors: Hurvitz SA, Guérin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D

Budget impact analysis of everolimus for ER+, HER2- metastatic breast cancer patients in the U.S.

Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)

Authors: Xie J, Diener M, De G, Wu EQ, Namjoshi M
Economic burden of hepatocellular carcinoma in China
Abstract: ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Poster)
Authors: Wu EQ, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J

Healthcare utilization and costs among lung cancer patients in China
Abstract: ISPOR 17th Annual International Meeting Poster Session, Washington, DC, 2-6 June, 2012 (Poster)

Monitoring and switching patterns in chronic myelogenous leukemia patients treated with imatinib: A chart review analysis
Abstract: ASCO Annual International Meeting, Chicago, IL, 1-5 June, 2012 (Poster)
Authors: Chen L, Guérin A, Guo A, Aberki C, Wu EQ, Ericson SG

Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia
Abstract: 2012 ASCO Annual Meeting, Chicago, IL, 1-5 June, 2012 (Poster)
Authors: Shi L, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Vander Velde NS

Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI)
Abstract: 2012 ASCO Annual Meeting, Chicago, IL, 1-5 June, 2012 (Published online only)
Authors: Bonthapally V, Wu EQ, Guérin A, Gauthier G, Cloutier M, Holen KD, Ray S

Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review
Abstract: 2012 ASCO Annual Meeting, Chicago, IL, 1-5 June, 2012 (Poster)

Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies
Abstract: 2012 ASCO Annual Meeting, Chicago, IL, 1-5 June, 2012 (Poster)
Authors: Hurvitz SA, Guérin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D

Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab vs. lapatinib: A retrospective analysis
Abstract: 2012 ASCO Annual Meeting, Chicago, IL, 1-5 June, 2012 (Poster)
Authors: Gauthier G, Guérin A, Styles A, Wu EQ, Brammer MG, Lalla D

Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis
Abstract: 2012 ASCO Annual Meeting, Chicago, IL, 1-5 June, 2012 (Poster)

Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases
Abstract: American Urological Association Annual Meeting, Atlanta, GA, 19-23 May, 2012 (Poster)
Authors: Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M

The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
Publication: Journal of Medical Economics. 2012 May. Authors: Guérin A, Wu EQ, Bollu VK, Williams D, Guo A, Ponce de Leon D, Quintas-Cardama A

Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia
Authors: Ulcickas Yood M, Oliveira SA, Cziraky M
Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN

Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer

*Authors:* Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB

Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial

*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antràs L, Neary MP, McCann L, Hodge R, Sternberg CN

Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients

*Authors:* Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ

Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma

*Publication:* Urol Oncol. 2011 Nov-Dec; 29(6): 756-63
*Authors:* Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Duh MS, Jayawant SS, Oh WK, Atkins MB, Choueiri TK

Number needed to treat and treatment cost per fracture avoided with denosumab compared to zoletronic acid in breast cancer patients with bone metastases

*Abstract:* 11th International Conference Cancer-Induced Bone Disease, Chicago, IL, 30 November-3 December, 2011 (Presentation), 2011 Breast Cancer Symposium, San Francisco, CA, 8-10 September, 2011 (Poster)
*Authors:* Xie J, Signorovitch JE, Diener M, Wu EQ, Namiishi M

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases

*Authors:* Xie J, Namiishi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW

The economics of the hematopoietic growth factors

*Review.*
*Authors:* Eldar-Lissai A, Lyman GH

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison of randomized trials

*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bolliu VK, Williams D, Wei Lj, DeAngelo Dj

Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison of randomized trials

*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bolliu VK, Williams D, Wei Lj, DeAngelo Dj
Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma
Authors: Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje

Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer
Authors: Yang H, Yu AP, Wu EQ, Yim YM, Yu E

Economic evaluation of denosumab compared to zoledronic acid in hormone-refractory prostate cancer patients with bone metastases
Abstract: 2011 American Society of Clinical Oncology Annual Meeting, Chicago, IL, 3-7 June, 2011 (Poster)
Authors: Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW

New methods to adjust for selective crossover in survival analysis: In assessments of cost-effectiveness of cancer therapies
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Workshop)
Authors: Delea TE, Duh MS, Wei LJ, Robins J

Real world clinical resource utilization of metastatic prostate cancer patients in the United States: Results from two large claims databases
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P

Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma in Ireland
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)

Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma in United Kingdom
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)

Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ

Transfusional Iron Overload (TIO) monitoring and treatment: Findings from an electronic medical records review study at the Moffitt Cancer Center and Research Institute
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Du MS, Wetzstein GA, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray LA

The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the United States
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Velde H, Duh MS
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy

*Authors:* Porta C, Paglino C, Imaisio I, Canipari C, Chen K, Neary M, Duh MS

The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: A retrospective study of the U.S. Veterans affairs population


Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia

*Authors:* Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD

Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia

*Abstract:* 2010 Annual Meeting of the American Society of Hematology, Orlando, FL, December 4-7, 2010 (Poster)
*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ

The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML)

*Abstract:* 2010 Annual Meeting of the American Society of Hematology, Orlando, FL (Poster)
*Authors:* Wu EQ, Guerin A, Bollu V, Williams D, Guo A, Ponce de Leon D, Yu AP, Quintas-Cardama A

Tolerability, efficacy, and safety of pegylated liposomal doxorubicin in combination with carboplatin versus gemcitabine-carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: A systematic review

*Authors:* Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S

Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX)

*Abstract:* Annals of Oncology. 2010 Oct; 21(supp 8):viii342. 35th European Society for Medical Oncology Congress, Milan, Italy, 8-12 October, 2010 (Poster)
*Authors:* Yim Y, Wu EQ, Yu AP, Yang H, Yu E

Comparing early intervention with zoledronic acid to no biophosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the U.S. Veterans Affairs (VA) population

*Abstract:* Cancer-Induced Bone Disease (CABS) 10th International Meeting, Sheffield, UK, 22-25 September, 2010 (Poster)
*Authors:* Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N

Patterns of treatment with angiogenesis inhibitors in patients with metastatic renal cell carcinoma (mRCC) in France

*Abstract:* J Clin Oncol. 2010; 28(supp). American Society of Clinical Oncology (ASCO) 2010 Annual Meeting, Chicago, IL, 4-8 June, 2010 (Poster)
*Authors:* Levy A, Gross-Goupil M, Sarda SP, Korves C, Antràs L, Luka A, Ramamarthy P, Neary M, Duh MS, Escudier B

Comparison of healthcare resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML)

*Authors:* Wu EQ, Bollu V, Guo A, Guérin A, Tsaneva M, Williams D, Griffin JD

Non-adherence to imatinib in chronic myeloid leukemia (CML) patients is associated with short- and long-term negative impacts on healthcare resource utilization and costs

*Authors:* Guérin A, Bollu V, Guo A, Wu EQ, Yu AP, Sirulnik LA, Griffin JD
Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab

Authors: Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS

Costs of treatment with angiogenesis inhibitors (AIs) in patients with metastatic renal cell carcinoma (mRCC): Results from a medical chart review study

Authors: Oh WK, McDermott DF, Duh MS, Antràs L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK

Health care costs associated with angiogenesis inhibitors (AIs) and mTOR inhibitors (mTORs) in patients with metastatic renal cell carcinoma (mRCC) treated at U.S. community oncology clinics

Authors: Chen K, Antràs L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P

Health care costs associated with multikinase inhibitors (MKIs) for treatment of metastatic renal cell carcinoma (mRCC) in a clinical practice setting in Italy

Authors: Paglino C, Porta C, Canipari C, Antràs L, Chen K, Whittemore S, Luka A, Ramamurthy P, Neary MP, Duh MS

Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study

Authors: Guérin A, Bollu V, Williams D

Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs)

Authors: Dial E, Duh MS, Antràs L, Rodermund D, Neary MP, Choueiri TK, Oh WK

Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States

Authors: Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, van de Velde H, Esseltine DL, Garrison L

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: Effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

Publication: BJU Int. 2010 May; 105(9):1247-54.

Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: A retrospective medical records review

Authors: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS

Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients

Authors: Wu EQ, Johnson S, Beau lieu N, Arana M, Bol lu V, Guo A, Coombs J, Feng W, Cortes J

Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: Observations from a large managed-care database

Authors: Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Piech CT, Lefebvre P
Risk of renal impairment after treatment with ibandronate versus zoledronic acid: A retrospective medical records review
Authors: Diel IJ, Weide R, Köppler H, Antrás L, Smith M, Green J, Wintfeld N, Neary M, Duh MS

Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia
Authors: Heaney ML, Toy EL, Vekeman F, Laliberté F, Dority BL, Perlman D, Barghout V, Duh MS

Cost implications of IV versus oral antiangiogenesis therapies in patients with advanced renal cell carcinoma: Retrospective claims database analysis
Authors: Duh MS, Dial E, Choueiri TK, Fournier AA, Antrás L, Rodermund D, Neary MP, Oh WK

Symptom assessment in relapsed small cell lung cancer: Cross-validation of the patient symptom assessment in lung cancer instrument
Authors: Chen L, Antrás L, Duh MS, Neary MP, O'Brien ME

Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: A retrospective claims database analysis
Authors: Duh MS, Weiner JR, Lefebvre P, Neary MP, Skarin AT

Psychometric validation of the patient symptom assessment in lung cancer instrument for small cell lung cancer
Authors: Chen L, Antrás L, Duh MS, Levy N, Neary MP, O'Brien ME, von Pawel J

Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients
Authors: Wu EQ, Mulani P, Farrell MH, Sleep D

Dose and cost comparison of erythropoietic agents in the inpatient hospital setting
Authors: Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS

The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid
Authors: Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antrás L, Smith M, Neary MP, Duh MS

Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations
Authors: Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS

Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors
Authors: Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchencko M, Boyce SP, Mallett D, Perez EA

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer
Authors: Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J

Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve
Authors: Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ
Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Luftkin E, Mallet D

The costs of cancer: Cancer-related conditions can add dramatically to overall costs of care

*Authors:* Crémieux PY, Slavin MB, Fendrick AM, Hiriak T, Kosicki G

The costs of cancer to a major employer in the United States: A case-control analysis

*Authors:* Barnett A, Birnbaum H, Crémieux PY, Fendrick AM, Slavin MB

Cost of outpatient blood transfusion in cancer patients

*Authors:* Crémieux PY, Barrett B, Anderson K, Slavin MB

Understanding the pharmacoeconomic profile of cancer

*Authors:* Crémieux PY, Birnbaum HG, Greenberg PE

Cost-effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anemia

*Publication:* Pharmacoeconomics. 1999 Nov; 16(5 Pt 1):459-72.
*Authors:* Crémieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB

OTHER CONDITIONS AND TOPICS

I dentifying high-value treatment populations in clinical trials and real-world data

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Workshop)
*Authors:* Signorovitch J, Shaw J, Betts K, Wu EQ

Real-world persistence with single versus multiple regimens for HIV-1 treatment

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J

Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J

Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: Simulating the effect of compliance on real-world effectiveness

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Iorio A, Krishnan S, Huynh L, Kamer P, Duh MS, Yermakov S

Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis: Modeling the effect of compliance

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Iorio A, Krishnan S, Huynh L, Kamer P, Duh MS, Yermakov S

Impact of chronic Hepatitis C (CHC) treatment on post therapy healthcare cost

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A

Contraindications for HCV therapy in U.S. patients with untreated chronic Hepatitis C

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ

Treatment patterns, healthcare resource utilization and costs in U.S. patients diagnosed with chronic Hepatitis C

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)
*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ
The role of health economics and outcomes research in health care reform in China
Authors: Liang W, Xie J, Fu H, Wu EQ

Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States
Authors: Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL

Cost utility of hub-and-spoke telestroke networks from societal perspective
Authors: Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, Wu EQ

Dose titration and serum testosterone level assessments in patients treated with topical testosterone
Abstract: SMSNA 19th Annual Fall Scientific Meeting, New Orleans, LA, November 21-24, 2013 (Poster)

Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA
Authors: Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS

Effects of care management and telehealth: A longitudinal analysis using Medicare data
Authors: Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG

Brazil’s conditional cash transfer program associated with declines in infant mortality rates
Author: Shei A

Medical, drug, and work loss costs of venous leg ulcers
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N

Direct and indirect cost burden of chronic Hepatitis C stratified by liver disease severity in privately insured patients
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Podium presentation)

Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naïve HIV-1 patients treated with atazanavir/ ritonavir versus darunavir/ ritonavir
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

Health care resource utilization (HRU) and costs associated with disease activity in systemic erythematosus (SLE): A retrospective observational cohort analysis
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Kan H, Guérin A, Wu EQ, Kaminsky M, Yu AP, Denio AE, Jhingran PM, Molta CT, Narayanan S

Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Podium presentation)
Authors: Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ

Matching-adjusted indirect comparisons: A simulation study of statistical performance
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Signorovitch J, Ayyagari R, Cheng D, Wu EQ

Investigator-initiated approach to address an optimization problem in designing cost-efficient studies
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Huynh L, Clark M, Frick K
Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex for treating invasive fungal infections in hospitalized patients

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)

*Authors:* Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ

Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy


*Authors:* Wu EQ, Forsythe A, Guérin A, Yu AP, Latremouille-Viau D, Tsaneva M

R1 Matching-adjusted indirect comparisons: A new tool for timely comparative effectiveness research


*Authors:* Signorovitch JE, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ

Identifying patient subgroups who benefit most from a treatment – using administrative claims data to uncover treatment heterogeneity


*Authors:* Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins PS, Wu EQ

The direct and indirect costs among U.S. privately insured employees with hypogonadism


*Authors:* Kaltenboeck A, Foster S, Ivanova JI, Diener M, Bergman R, Birnbaum HG, Kinchen K, Swindle R

Real-world role of tricyclic antidepressants in the treatment of fibromyalgia


*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R

Duloxetine use in chronic low back pain: Treatment patterns and costs


*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC, 2-6 June, 2012 (Podium)

*Authors:* Xie J, Juday T, Swallow E, Du EX, Uy J, Hebden T, Signorovitch JE

Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States

*Abstract:* 11th American Society for Microbiology Conference on Candida and Candidiasis, San Francisco, CA, 29 March – 2 April, 2012 (Poster)

*Authors:* Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D

Confounding factors in off-label drug use

*Publication:* Health Aff (Millwood). 2012 Feb; 31(2):460; author reply 460.

*Authors:* Greenberg PE, Pike C, Sisitsky T

In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty


*Authors:* Vekeman F, Lamori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P

Rates and predictors of chlamydia re-screening among privately insured patients with chlamydia in 2007- 2009

*Abstract:* 2011 ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)

*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu EQ

Rates and predictors of gonorrhea re-screening among privately insured patients with gonorrhea in 2007-2009

*Abstract:* 2011 ISPOR 14th Annual European Congress, Madrid, Spain, 5-8 November, 2011 (Poster)

*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu EQ

Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes

*Abstract:* ACR/ARHP Annual Scientific Meeting, Chicago, IL, 4-9 November, 2011

Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout

*Abstract*: ACR/ARHP Annual Scientific Meeting, Chicago, IL, 4-9 November, 2011.
*Authors*: Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu AP, Wu EQ, Liu J, Shi L

Implementation of the biosimilar pathway: Economic and policy issues

*Authors*: Grabowski HG, Long G, Mortimer R

Interprofessional education about decision support for patients across cultures


Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act

*Authors*: Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N

Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings

*Authors*: Baker LC, Johnson SJ, Macaulay D, Birnbaum H

Utilizing rich data sources to identify patients’ subgroups that can benefit most from a treatment

*Abstract*: The 3rd DEcIDE Symposium On Comparative Effectiveness Research Methods. Maryland, 6-7 June, 2011 (Workshop)
*Authors*: Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawan J, Hodgkins P, and Erder MH

Comparative effectiveness research using matching-adjusted indirect comparison - A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data

*Abstract*: The 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, MD, 6-7 June, 2011 (Workshop)
*Authors*: Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P and Erder MH

The direct and indirect costs associated with hypogonadism among U.S. privately-insured employees

*Abstract*: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Podium)
*Authors*: Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R

Improved indirect treatment comparisons for comparative effectiveness research

*Abstract*: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Workshop)
*Authors*: Signorovitch J, Navarro R, Betts K, Wu EQ

Healthcare resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer’s perspective

*Abstract*: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
*Authors*: Jensen JF, Lefebvre P, Laliberté F, Sarda SP, Law A, Pocoski J, Duh MS

Direct and indirect costs of privately-insured patients treated with oxymorphone extended-release or oxycodone controlled-release tablets

*Abstract*: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
*Authors*: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, Summers KH

Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy

*Authors*: Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder MH, Bose A
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population
Publication: J Med Econ. 2011; 14 (3):324-34.
Authors: Vekeman F, LaMori JC, Laliberté F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P

Real-world practice patterns, health-care utilization, and costs in patients with low back pain: The long road to guideline-concordant care
Authors: Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW

Analysis of genetic diversity of gemplasm of Pinellia ternata based on SRAP
Authors: Yang M, Chen K

Epidemiologic evaluation of cardiovascular risk in patients receiving milnacipran, venlafaxine, or amitriptyline: Evidence from French health data
Authors: Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guérin A, Boerstoel-Streefland M, Jiang W, Lefebvre P

Data exclusivity for biologics
Authors: Grabowski HG, Long G, Mortimer R.

Care and costs: The sustained cost impact of reduced hospitalizations in a partnership-measurement model of disease management
Publication: Healthcare Quarterly 2010; 13(4).
Authors: Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T

Persistence with nebivolol compared to other β-blockers in the treatment of hypertension: A retrospective claims analysis
Authors: Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ

Racial differences in use of biologics for Crohn’s disease in a Medicaid population
Abstract: American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, 15-20 October, 2010 (Poster)
Authors: Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R

Introducing perspectives on comparative effectiveness research
Authors: Birnbaum HG, Greenberg PE

Perspectives on comparative effectiveness research: Views from diverse constituencies
Authors: Nellesen D, Birnbaum HG, Greenberg PE

Selecting the optimal target population for formulary coverage
Abstract: ISPOR 4th Asia-Pacific Conference, Phuket, Thailand, 5-7 September 2010 (Workshop)
Discussion Leaders: Wu EQ, Yu D, Xie J, Gu

Methodological issues in a meta-analysis
Author: Crémieux PY

Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy
Conference: BIO International Convention, Chicago, IL, 6 May, 2010.
Panelists: Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T
Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis

Authors: Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP

Relationship between daily dosing frequency, compliance, healthcare resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD)

Authors: Toy EL, Beaulieu NU, McHale J, Welland TR, Plauschinat C, Swensen A, Duh MS

Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD)

Authors: Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS

The role of compliance in telehealth adoption

Authors: Newell D, Johnson S, Rutherford P, Welte I

Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy
Conference: BIO International Convention, Chicago, IL, 6 May, 2010.
Panelists: Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T

The risks and costs of multiple-generic substitution of topiramate

Authors: Sethi NK, Torgovnick J, Sethi PK, Arsura E, Emmanuel Paradis P, Duh MS, Durkin MB, Wan GJ

Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries
Authors: Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafuente ML, Lefebvre P, Gaudig M, Duh MS

A study on the economic impact of bariatric surgery
Authors: Crémieux PY, Buchwald H, Shikora SA, Ghosh A, Yang E, Buessing M

Clinical consequences of generic substitution of lamotrigine for patients with epilepsy
Publication: Neurology. 2008 May 27; 70(22 Pt 2):2179-86.
Authors: LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O

Economic impact of generic substitution of lamotrigine: Projected costs in the U.S. using findings in a Canadian setting
Authors: LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O

Disease-related and all-cause health care costs of elderly patients with gout
Publication: J Manag Care Pharm 2008 Mar; 14(2):164-75.
Authors: Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E

The role of epidemiology in drug safety litigations
Publication: Update. 2007 Nov/Dec: 31-34.
Authors: Duh MS, Greenberg PE, Weiner JR

The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: The case of lamotrigine
Authors: Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Crémieux PY
Authorized generic drugs, price competition, and consumers’ welfare
Authors: Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E

Compulsory generic switching of antiepileptic drugs: High switchback rates to branded compounds compared with other drug classes
Authors: Andermann F, Duh MS, Gosselin A, Paradis PE

Retrospective economic and outcomes analyses using non-U.S. databases: A review
Publication: Pharmacoeconomics. 2007; 25(7):563-76.
Authors: Shi L, Wu EQ, Hodges M, Yu AP, Birnbaum HG

Do drugs reduce utilization of other healthcare resources?
Authors: Crémieux PY, Ouellette P, Petit P

A roundtable discussion: The importance of causation analysis in mass tort cases
Publication: FDLI Update November/December 2006.
Authors: Greenberg PE, Lykos G, Gourley S, Davies C.

Generic competition in the U.S. pharmaceutical industry
Authors: Saha A, Grabowski HG, Birnbaum HG, Greenberg PE, Bizan O

The market for follow-on biologics: How will it evolve?
Authors: Grabowski H, Cockburn I, Long G

A regulatory perspective on productivity claims: Implications for future productivity research
Authors: Greenberg PE, Birnbaum HG

Linking administrative claims data with archival productivity measures to inform employer decision making
Authors: Greenberg PE, Birnbaum HG

Hospital cost flexibility in the presence of many outputs: A public-private comparison
Authors: Crémieux PY, Ouellette P, Rimbaud F, Vigeant S

Public and private pharmaceutical spending as determinants of health outcomes in Canada
Authors: Crémieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K

Your patent is about to expire: What now?
Authors: Parece A, Tuttle E, Hector A

Product liability in the pharmaceutical industry
Authors: Crémieux PY, Greenberg PE

Administrative claims data: A valuable tool in pharmaceutical litigation
Authors: Birnbaum HG, Greenberg PE

Measuring hospital efficiency in the presence of quasi-fixed inputs: An analysis of Québec hospitals
Authors: Bilodeau D, Crémieux PY, Jauoard B, Ouellette P, Vovor T

The relationship between technology availability and health care spending
Authors: Baker L, Birnbaum HG, Geppert J, Mishol D, Moyneur E
Switching costs, price sensitivity and health plan choice
Authors: Strombom BA, Buchmueller TC, Feldstein PJ

Hospital technology in a non-market health care system
Authors: Bilodeau D, Crémieux PY, Ouellette P

L’évaluation de l’efficience budgétaire des CLSC au Québec à partir de la méthode DEA (An evaluation of the budgetary efficiency of local community clinics in Quebec based on a DEA approach)
Authors: Crémieux PY, Gadbois D, Jaumard B, Ouellette P, Vovor T

Pharmaceutical spending and health outcomes in the United States
Authors: Greenberg PE, Crémieux PY, Ouellette P, Meilleur MC, Leong SA

The effects of chronic medical conditions on work loss and work cutback
Authors: Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS

Actual and perceived impacts of tobacco regulation on restaurants and firms
Authors: Crémieux PY, Ouellette P

Omitted variable bias and hospital costs
Authors: Crémieux PY, Ouellette P

Impact of illness and its treatment on workplace costs: Regulatory and measurement issues
Authors: Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P

Diagnosing the illness
Authors: Crémieux PY, Ouellette P

Hospital cost function in a non-market health care system
Authors: Bilodeau D, Crémieux PY, Ouellette P

Health care spending as determinants of health outcomes
Authors: Crémieux PY, Ouellette P, Pilon C

Pharmacoeconomics and health policy: Current applications and prospects for the future
Authors: Greenberg PE, Arcelus A, Birnbaum HG, Crémieux PY, LeLorier J, Ouellette P, Slavin MB

Using healthcare claims data for outcomes research and pharmacoeconomic analyses
Authors: Birnbaum HG, Crémieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L

Tackling costs one disease at a time
Author: Greenberg PE

Calculating return on investment from reducing workplace costs of illness
Authors: Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J

La performance des CLSC au Quebec, (Local health clinic performance in Quebec)
Authors: Crémieux PY, Ouellette P, Gadbois D

The home infusion therapy/relative benefit index: Summary of an analysis using insurance claims data
Authors: Birnbaum HG, Tang M
Etude d’impact du projet de loi sur le tabac
(Impact report on the proposed tobacco law)
Authors: Crémières PY, Fortin P, Lavoie F, Ouellette P, St Pierre Y

The next phase of managed care: Targeting investments in employee health
Publication: On Managed Care. 1997 Sept.
Authors: Greenberg PE, Berndt E, Finkelstein S

Une analyse du contexte budgétaire de l’activité médicale au Québec (An analysis of the budgetary context of medical activity in Québec)
Authors: Crémières PY, Ouellette P

Economic consequences of illness in the workplace
Authors: Greenberg P, Finkelstein S, Berndt E

Consolidation and restructuring: The next step in managed care
Authors: Danzon PM, Boothman LG, Greenberg PE

Calculating the workplace cost of chronic disease
Authors: Greenberg PE, Finkelstein SN, Berndt ER

When can a Medicare insured group (MIG) succeed?
Authors: Birnbaum HG, Causino N, Lang K

Savings estimate for a Medicare insured group
Authors: Birnbaum HG, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP

An alternative in terminal care: Results of the National Hospice Study
Authors: Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, Birnbaum HG

Impacts of the New York long-term home health care program
Publication: Medical Care. 1986; 24(7).
Authors: Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellington-Otto K

What does hospice cost?
Authors: Birnbaum HG, Kidder D

Implementing community based long-term care: Experience of the long-term home health care program
Publication: The Gerontologist. 1984 Summer; 24(4).
Authors: Birnbaum HG, Burke R, Swearingen C, Dunlop B

How does the nursing home sector behave: A multi-equation model of nursing home behavior
Authors: Birnbaum HG, Lee AJ, Bishop C

National hospice study analysis plan
Authors: Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum HG

Managing programs for the elderly: Design of a social information system
Authors: Birnbaum HG, Burke R, Pratter F

Home care in hospices
Authors: Birnbaum HG, Mor V, Greer DS

The determinants of nursing home operating costs in New York State
Authors: Lee AJ, Birnbaum HG

Medicare legislation for hospice care: Implications of national hospice study data
Authors: Mor V, Birnbaum HG
Why do nursing home costs vary? The determinants of nursing home costs  
*Authors:* Birnbaum HG, Bishop C, Lee AJ, Jensen G

OVERACTIVE BLADDER

Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder  
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)  
*Authors:* Ivanova J, Hayes-Larson E, Sorg RA, Birnbaum HG, Fitzmartin J, Berner T

The healthcare cost impacts of switching antimuscarinic agents among patients with overactive bladder in a privately insured population  
*Authors:* Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H

Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder  
*Abstract:* ISPOR 18th Annual International Meeting, 18-22 May, 2013, New Orleans, LA (Poster)  
*Authors:* De G, Yang H, Runken MC, Yan Y, Kelkar S, Bui CN, Xie J, Wu EQ

Cost-effectiveness analysis of mirabegron vs. tolterodine extended-release in the treatment of patients with overactive bladder in the United States  
*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany, 3-7 November, 2012 (Poster)  
*Authors:* Xie J, Zhou ZY, Bui CN, Yan SY, De G, Runken CM, Wu EQ

Employees with overactive bladder: Work loss burden  
*Authors:* Wu EQ, Birnbaum HG, Marynchenko M, Mareva M, Williamson T, Mallett D

PAIN AND PRESCRIPTION OPIOIDS

The burden of opioid abuse among commercially insured patients  
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)  
*Authors:* Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R

Differences between high-cost and low-cost patients diagnosed with opioid abuse  
*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada, May 31-June 4, 2014 (Poster)  

Medical resource use and costs among pain patients with potential opioid tolerability issues  
*Abstract:* ICOO 2014, Boston, MA, 8-10 June, 2014 (Poster) (forthcoming)  
*Authors:* Birnbaum H, Kirson N, Shei A

Characteristics of high-cost patients diagnosed with opioid abuse  
*Abstract:* AMCP 2014, Tampa, FL, 1-4 April, 2014 (Poster)  
*Authors:* Birnbaum H, Kirson N, Shei A

Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation  
*Abstract:* AMCP 2014, Tampa, FL, 1-4 April, 2014 (Poster)  
*Authors:* Birnbaum H, Kirson N, Shei A

Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database  
*Abstract:* AMCP 2014, Tampa, FL, 1-4 April, 2014 (Poster)  
*Authors:* Birnbaum H, Kirson N, Shei A

Use of prescription opioids with abuse-deterrent technology to address opioid abuse  
*Publication:* Current Medical Research and Opinion. 2014 April 24.  
*Authors:* Kirson NY, Shei A, White AG, Birnbaum HG
The relationship between positive subjective measures in abuse liability studies and real-world non-medical use: Potential impact of abuse deterrent opioids on rates of non-medical use and associated healthcare costs

Abstract: AAPM 2014, Phoenix, AZ, 6-9 March, 2014 (Poster)
Authors: White A, LeCates J, Cheng W

Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the U.S.
Authors: Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E

Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management
Authors: Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekian J, Sheng M

A meta-analysis of efficacy and safety of prescription opioids, including formulations with tamper-resistant technologies, in non-cancer pain management
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Michna E, Kirson N, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter L

Estimating the payer-specific excess medical costs of opioid abuse in the U.S.
Abstract: ISPOR 18th Annual International Meeting, New Orleans, LA, May 18-22, 2013 (Poster)
Authors: Michna E, Kirson N, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter L

Prescription opioid abuse: Challenges and opportunities for payers
Authors: Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG

A model to identify patients at risk for prescription opioid abuse, dependence, and misuse
Authors: Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL

Direct and indirect costs of patients treated with extended-release oxymorphone HCl or controlled-release oxycodone HCl
Authors: Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH

Direct and indirect costs associated with Dupuytren's contracture
Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications

Removal of opioid/acetaminophen combination prescription pain medications: Assessing the evidence for hepatotoxicity and consequences of removal of these medications
Authors: Michna E, Duh M, Korves C, Dahl J

Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications
Authors: Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE
Societal costs of opioid abuse, dependence, and misuse in the United States

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)
*Authors:* Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL

Real-world use of duloxetine for low back pain and chronic low back pain: Treatment patterns, direct and indirect costs

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA, 15-19 May, 2010 (Poster)
*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R

Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction

*Authors:* White AG, Birnbaum HG, Rothman DB, Katz N

Analytic models to identify patients at risk for prescription opioid abuse

*Authors:* White AG, Birnbaum HG, Schiller M, Tang J, Katz NP

Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia

*Publication:* Pain. 2009 Sep; 10(9):976-83.
*Authors:* White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG

Employees with fibromyalgia: Medical comorbidity, healthcare costs, and work loss

*Authors:* White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL

Foundations of opioid risk management

*Authors:* Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Cicero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslck J, Lande SD

Estimated costs of prescription opioid analgesic abuse in the United States in 2001: A societal perspective

*Authors:* Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP

Economic burden of illness for employees with painful conditions

*Authors:* White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA

Direct costs of opioid abuse in an insured population in the United States

*Authors:* White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N

Economic cost and epidemiological characteristics of patients with fibromyalgia claims

*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ

RESPIRATORY DISEASE

Pulmonary medication adherence and healthcare utilization in cystic fibrosis

*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA

A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care


Development and validation of a claims-based prediction model for COPD severity

*Authors:* Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care

Development and validation of a claims-based prediction model for COPD severity
*Publication*: Respir Med. 2013 June 24. [Epub Ahead of Print]
*Authors*: Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF

Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China
*Abstract*: ISPOR 17th Annual International Meeting Poster Session, Washington, DC, 2-6 June, 2012 (Poster)

Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care
*Authors*: Sawicki G, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Shi L

Bioevaluation study of (32)P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model
*Authors*: Xu YP, Yang M, Pan DH, Wang LZ, Liu L, Huang P, Shao G

Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
*Authors*: Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L

Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD
*Authors*: Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SL, Setyawan J

Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a U.S. privately insured population
*Authors*: Kirson NY, Bimbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T

Development of a pulmonary exacerbation risk score among CF patients not receiving recommended therapies for pulmonary care
*Abstract*: 25th NACFC Annual Meeting, Anaheim, CA, 3-5 November, 2011 (Presentation)

Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008
*Abstract*: 25th NACFC Annual Meeting, Anaheim, CA, 3-5 November, 2011 (Poster)
*Authors*: Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch JE, von Wartburg M, Wu EQ, Shi L

Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis
*Abstract*: 25th NACFC Annual Meeting, Anaheim, CA, 3-5 November, 2011 (Poster)

Cost-effectiveness analysis of roflumilast/tiotropium combination therapy versus tiotropium monotherapy in patients with severe to very severe COPD
*Authors*: Yu AP, Sun SX, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu EQ

Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis
*Authors*: Signorovitch J, Sawicki GS, Zhang J, Latremouille-Viau D, Wu EQ, von Wartburg M, Lizheng S
Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases

Abstract: ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
Authors: Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P

Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD

Authors: Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ

Treatment of COPD: Relationships between daily dosing frequency, adherence, resource use, and costs

Authors: Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS

Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers

Authors: Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI

Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers

Authors: Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI

Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs. single long-acting inhalers

Authors: Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI

Comparison of drug costs and clinical outcomes with tobramycin solution for inhalation and aztreonam lysine for inhalation in cystic fibrosis

Abstract: The 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD, 21-23 October, 2010 (Poster)
Authors: Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J

The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: A review

Authors: Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS

Economic burden of exacerbations in chronic obstructive pulmonary disease

Authors: Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J

Relationship between daily dosing frequency, compliance, healthcare resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD)

Authors: Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS
Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations
Authors: Ivanova J, Bergman R, Birnbaum H, Colice G, Silverman R, McLaurin K

Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin
Authors: Signorovitch JE, Duh MS, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D

Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: A systematic review of fluticasone/ budesonide and formoterol/ salmeterol
Authors: Frois C, Wu EQ, Ray S, Colice GL

Costs and resource use of mild persistent asthma patients initiated on controller therapy
Authors: Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C

Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: A review of the literature
Authors: Weiner JR, Toy EL, Sacco P, Duh MS

Use of inhaled corticosteroids and healthcare costs in mild persistent asthma
Authors: Colice GL, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB

Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: A cohort study
Authors: Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF

Development of a COPD severity score
Authors: Wu EQ, Birnbaum HG, Cifaldi M, Kang YJ, Mallett D, Colice GL

Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population
Authors: Colice GL, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Varghese S

Treatment costs of community-acquired pneumonia in an employed population
Authors: Colice GL, Morley MA, Asche C, Birnbaum HG

CRIT study group. Red blood cell transfusion and ventilator-associated pneumonia: A potential link?
Authors: Shorr AF, Duh MS, Kelly KM, Kollef MH

Lower respiratory tract infections: Impact on the workplace
Authors: Birnbaum HG, Morley M, Leong S, Greenberg PE, Colice GL

Economic burden of respiratory infections in an employed population
Authors: Birnbaum HG, Morley M, Greenberg PE, Colice GL

Direct and indirect costs of asthma to an employer
Authors: Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA

Economic burden of pneumonia in an employed population
Authors: Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL
Lack of intraocular pressure effect of budesonide inhalation therapy in a mixed asthmatic population
Authors: Duh MS, Walker AM, Lindmark B, Laties AM

Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis
Authors: LeLorier J, Perreault S, Birnbaum HG, Greenberg PE, Sheehy O

RHEUMATOLOGY
Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes
Publication: Appl Health Econ Health Policy. 2014 Feb 27.
Authors: Oglesby A, Korves C, Laliberté F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS

Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: results from the ABILITY-2 clinical trial
Authors: Mease PJ, Rao S, Betts KA, Lu M, Fan L, Pangan AL, van der Heijde D, Cifaldi MA

A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus
Authors: Kan H, Guérin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Jhingran P, Narayanan S, Molta C

Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis
Publication: J Med Econ. 2013 Feb 7. [Epub ahead of print]
Authors: Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M

Benefits of treat-to-target guideline compliance in patients with rheumatoid arthritis: A retrospective claims analysis
Abstract: American College of Rheumatology Annual Meeting, Washington, DC, 10-14 November, 2012 (Poster)
Authors: Bergman M, Shaw JW, Cifaldi MA, Guérin A, Chopra P, Signorovitch JE

Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis
Abstract: American College of Rheumatology Annual Meeting, Washington DC, United States, 10-14 November, 2012 (Poster)
Authors: Bergman M, Shaw JW, Cifaldi MA, De G, He T, Ayyagari R, Signorovitch JE

Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone
Authors: Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P

Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs. etanercept
Abstract: ACR/ARHP Annual Meeting Annual Meeting in Washington, DC, 9-14 November, 2012 (Poster)
Authors: Xie J, Ganguli A, Yang HY; Parikh K, Wu EQ, Cifaldi M

Healthcare costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying antirheumatic drug (DMARDs) or methotrexate (MTX)
Abstract: ACR/ARHP Annual Meeting; November 9-14, 2012; Washington, DC.
Authors: Zhang F, Hiscock R, Curtis JR

Health care costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying anti-rheumatic drug (DMARDs)
Authors: Zhang F, Hiscock R, Curtis JR
Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on non-biologic disease modifying anti-rheumatic drugs (DMARDS)

Abstract: ISPOR 15th Annual European Congress 2012, ICC Berlin, Germany, 6 November, 2012 (Poster)
Authors: Curtis J, Gauthier G, Hiscock R, Zhang F

The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials

Abstract: Annual European Congress of Rheumatology - EULAR 2012, Rheumatology Medical Congress, Germany, Berlin, 2012 6-9 June 2012 (Poster)
Authors: Burmester G, Signorovitch JE, Bao Y, Valdes J, Williams D, Mulani PM, Emery P

Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on oral disease-modifying anti-rheumatic drugs (DMARDS)

Abstract: Annual European Congress of Rheumatology EULAR 2012, Germany, 6-9 June, 2012
(Presentation)
Authors: Zhang F, Guérin A, Gauthier G, Curtis J

Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006
Authors: Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M

Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells

Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States
Abstract: ACR/ARHP Annual Scientific Meeting, Chicago, IL, 4-9 November, 2011 (Poster)
Authors: Guérin A, Gauthier G, Day R, Khan Z, Zhang F

Prevalence of autoimmune diseases and other comorbidities in patients with psoriatic arthritis in the United States
Abstract: ACR/ARHP Annual Scientific Meeting, Chicago, IL, 4-9 November, 2011 (Poster)
Authors: Zhang F, Guérin A, Gauthier G, Day R, Khan Z

Economic burden of psoriatic arthritis and obesity in patients with psoriatic arthritis in the United States
Abstract: ACR/ARHP Annual Scientific Meeting, Chicago, IL, 4-9 November, 2011 (Poster)
Authors: Zhang F, Guérin A, Latremouille-Viau D, Day R, Khan Z

Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid arthritis

Indirect comparison of adalimumab vs. etanercept for the treatment of psoriatic arthritis
Abstract: ISPOR 16th Annual International Meeting, Baltimore, Maryland, 21-25 May, 2011 (Poster)
Authors: Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi MA

Direct and indirect costs of spondyloarthritis patients pre- and post-diagnosis
Abstract: American College of Rheumatology/Association of Rheumatology Health Professionals 74th Annual Scientific Meeting, Atlanta, Georgia, 7-11 November, 2010 (Poster)
Authors: Kirson N, Birnbaum HG, Rao S, Swallow KE, Waldman T, Dayoub E, Cifaldi M

Racial differences in use of biologics for Crohn’s disease in a Medicaid population
Abstract: American College of Gastroenterology Annual Scientific Meeting, San Antonio, Texas, 15-20 October, 2010 (Poster)
Authors: Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R
Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis

*Authors:* Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M

**Societal cost of rheumatoid arthritis patients in the U.S.**
*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M

**Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis**
*Authors:* Birnbaum H, Pike C, Kaufman R, Cifaldi M

**Workplace impacts of anti-TNF therapies in rheumatoid arthritis:** Review of the literature
*Authors:* Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M

**Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States**
*Authors:* White AG, Birnbaum HG, Janagap C, Buteau S, Schein J

**Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis**
*Authors:* Wu EQ, Chen L, Birnbaum HG, Yang E, Cifaldi M

**Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data**
*Authors:* Wu EQ, Chen L, Birnbaum HG, Yang E, Cifaldi M

**Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial**

**Direct and indirect costs of rheumatoid arthritis to an employer**
*Authors:* Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC

**WOMEN'S HEALTH**

**Systematic literature review of the costs of pregnancy in the U.S.**
*Authors:* Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS

**Medicaid spending on contraceptive coverage and pregnancy-related care**
*Authors:* Laliberté F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P

**Economic burden and quality of life of vulvodynia in the United States**
*Authors:* Xie Y, Shi L, Xiong X, Wu EQ, Veasley C, Dade C

**Cost burden and treatment patterns associated with management of heavy menstrual bleeding**
*Authors:* Jensen JT, Lefebvre P, Laliberté F, Sarda SP, Law A, Pocoski J, Duh MS

**Effects of quinestrol and levonorgestrel on populations of plateau pikas, Ochotona curzoniae, in the Qinghai-Tibetan Plateau**
Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy
*Authors:* Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P

Healthcare resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer’s perspective
*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
*Authors:* Jensen JF, Lefebvre P, Laliberté F, Sarda SP, Law A, Pocoski J, Duh MS

Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy
*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD, 21-25 May, 2011 (Poster)
*Authors:* Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P

Annual costs associated with diagnosis of uterine leiomyomata
*Authors:* Hartmann KE, Birnbaum HG, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P

A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis
*Authors:* Wu EQ, Birnbaum HG, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ

Lifetime costs of patients with clinically-detected uterine fibroids: An employer’s perspective
*Authors:* Wu EQ, Ben-Hamadi R, Birnbaum HG, Farrell MH, Spalding J, Stang P, Hartmann KE

Assessing the economic impact of chronic conditions in postmenopausal women
*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population
*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D

Lifetime medical costs for women: Cardiovascular disease, diabetes, and stress urinary incontinence
*Authors:* Birnbaum HG, Leong S, Kabra A
ABOUT ANALYSIS GROUP
Analysis Group provides health outcomes research and economic consulting to leading corporations and government agencies. The firm has more than 550 professionals, with U.S. offices in Boston, Chicago, Dallas, Denver, Los Angeles, Menlo Park, New York, San Francisco, and Washington DC, and internationally in Montreal, Canada and Beijing, China.

www.analysisgroup.com